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ABSTRACT OF THE DISSERTATION
Gene Delivery of Adenoviral-TMBIM6 Vector Protects the Neonatal Brain after
Hypoxic-Ischemic Injury
by
Desislava Doycheva
Doctor of Philosophy, Graduate Program in Physiology
Loma Linda University, June 2018
Dr. John H. Zhang, Chairperson
Neonatal hypoxia ischemia (HI) is an injury caused to the immature brain due to
reduced cerebral blood flow which is associated with life-long neurological impairments.
HI causes oxidative protein folding in the endoplasmic reticulum (ER), which results in
ER stress. Generation of reactive oxygen species (ROS), from cytochrome P450
members (CYP) and NADPH-P450 reductases (NPR), in combination with activation of
the unfolded protein response (UPR) are two major consequences of ER stress that cause
oxidative damage and cell death.
Herein we identified the role of Bax Inhibitor-1 (BI-1), an evolutionary conserved
protein encoded by the Transmembrane Bax inhibitor Motif Containing 6 (TMBIM6)
gene, in protection from ER stress after HI injury in the neonatal rat. As BI-1 has
multimodal properties that can target a wide array of pathophysiological consequences
after injury, our main objective was to evaluate BI-1’s protective mechanisms by
overexpressing it, using viral-mediated gene delivery of human adenoviral-TMBIM6
(Ad-TMBIM6) vector, in an in vitro and in vivo model of HI.
Following the Rice-Vannuci model, ten-day old (P10) rat pups underwent rightunilateral carotid artery ligation followed by 1.5h of hypoxia. Our results showed that
overexpression of BI-1 ameliorated short and long-term deficits following HI. There was
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a significant reduction in percent infarcted area which was linked with attenuation of
apoptosis, reduction of ROS accumulation and inhibition of pro-inflammatory mediators.
BI-1 mediated protection was observed to be via both inhibition of IRE1α signaling, a
stress sensor protein part of the UPR response, and P4502E1 activity, a major contributor
of ROS generation. Attenuation of apoptosis was associated with a decrease in IRE1αXBP1 levels while decreased levels of P4502E1 coupled with upregulation of Nrf-2 and
HO-1, anti-oxidant enzymes, were correlated with a reduction in ROS generation and
inflammation.
In conclusion we established that overexpression of BI-1 attenuated the
morphological and neurological consequences post HI via inhibition of ER stress induced
pathways. This new finding may help to provide a basis for BI-1 as a potential
therapeutic target.
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CHAPTER ONE
INTRODUCTION
Neonatal Hypoxia Ischemia
Neonatal Hypoxic-ischemic (HI) brain injury, caused by asphyxia, remains the
leading cause of neonatal morbidity and mortality (Volpe 1976). The predominant
pathogenic mechanisms of asphyxia are, hypoxemia, which is reduced amount of oxygen
in the blood supply, or reduced cerebral blood flow (ischemia), which is a diminished
amount of blood perfusing the brain. The term asphyxia is clinically used to describe an
impairment in placental or pulmonary gas exchange before, during or soon after birth and
is diagnosed as hypoxic ischemic encephalopathy (HIE) (Volpe 2001).
Impaired gas exchange may be from the fetus, the mother or uteroplacental
disruption. Fetal causes may result from umbilical cord complications, fetomaternal
hemorrhage and cardiac arrhythmia. Maternal causes may result from cardiac arrest,
hypovolemic shock, asphyxiation, status epilepticus or severe anaphylactoid reaction.
Uteroplacental causes are due to placental abruption or infection, cod prolapse, uterine
rupture or hyperstimulation (Rootwelt et al. , 1995). Generally, the newborn can
compensate for brief periods of depleted oxygen, however, if the asphyxia lasts too long
brain tissue is destroyed. These adverse events that occur to the newborn immature brain
often lead to severe impairments such as pulmonary immaturity, respiratory distress
syndrome, hypercapnia, hypo perfusion, mental retardation, epilepsy, cerebral palsy,
seizures and long-term cognitive and behavioral deficits.
HIE is increasingly becoming burdensome not only for the patients and their
families but also for the US healthcare with lifelong costs projected for cerebral palsy
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alone at $11.5 billion (Wirrell et al. , 2001; Bracewell et al. , 2002; Ferriero 2004; Bartha
et al. , 2007; Derrick et al. , 2007). Therefore, it is imperative to investigate and
understand HIE pathophysiology and signaling pathways to help us establish successful
treatment strategies for the management of these patients.

Epidemiology
HIE is a major burden of disease to not only patients but also their families with
more than a million children who survive birth asphyxia develop long-term complications
such as cerebral palsy, mental retardation and cognitive and behavioral deficits (Ferriero
2004; Zanelli et al. , 2011). The prevalence of HIE in developing countries is reported to
be 10 times higher compared to technologically advanced countries. In the United states
alone, the incidence is 1-4 cases per 1000 births. According to the World Health
Organization, 23% of neonates worldwide have birth asphyxia (920,000 neonatal deaths)
while causing another 1.1 million intrapartum stillbirths (Volpe 2001; Cerio et al. , 2013).
From the patients that experience moderate to severe HIE, mortality rates are reported at
23-50% prior to discharge, and between 37-38% at a 18-22month follow up (Gluckman
et al. , 2005; Shankaran et al. , 2005). Moreover, 80% of the cases that experience severe
encephalopathy develop serious long-term complications and approximately 30-50% of
those that survive with moderate to severe injury will develop long-term complications
(Vannucci et al. , 1999; Zanelli et al. , 2011). Some cases in newborn infants that do not
present neurological deficits at the initial period, may later develop long-term functional
impairments. In a clinical study of children 7+ years old that had a history of moderately
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severe HIE, 15-20% of them developed learning difficulties, despite no obvious signs of
brain injury (Robertson et al. , 2006; van Handel et al. , 2007).

Pathophysiology
Injury to the neonatal brain as a result of reduced cerebral blood flow and oxygen
supply are the primary biological processes that lead to hypoxic-ischemic encephalopathy
(HIE) (Grow et al. , 2002; Ferriero 2004; Perlman 2004). The amount of damage that the
newborn sustains depends on the duration of insult, the age and apoptosis rate (Zanelli et
al. , 2011).
In the initial stages of depleted oxygen and blood supply to the brain, the neonate
compensates for it by increasing cerebral blood flow (CBF) and redistributing the blood
to the vital organs such as the brain, heart and adrenal glands. However, once this initial
compensatory mechanism fails, CBF falls, blood pressure falls, and brain injury occurs.
This leads to intracellular energy failure (Vannucci et al. , 2005; Hagberg et al. , 2016).
In the primary energy failure stage, which occurs minutes after the insult, the
sodium potassium ATP pump will begin to fail which will result in accumulation of
sodium and calcium ions. This will induce neuronal depolarization and release of
excitatory amino acids, such as glutamate, that can trigger further pathological cascade
activation. Accumulation of calcium will recruit several enzymes, phospholipases,
endonucleases and proteases, which results in cytoskeletal and DNA damage. At this
stage apoptotic and necrotic cascades are activated which will cause cells to die (Hagberg
et al. , 2016).
Just before secondary energy failure occurs, there is an increase in free radical
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production and calcium overload which causes oxidative stress, excitotoxicity,
inflammation and apoptosis. The neonatal brain is highly susceptible to oxidative stress
due to the low concentrations of antioxidants present and high consumption of oxygen.
Cells will then begin to release pro-inflammatory cytokines which initiates an
inflammatory response (Ferriero 2004). The second energy failure occurs 24-48h after
injury and is characterized by mitochondrial dysfunction which leads to the ‘delayed
phase of neuronal injury’ (Fatemi et al. , 2009; Lai et al. , 2011; Hagberg et al. , 2016),
which is correlated with adverse neurodevelopmental outcomes.
This window between primary and secondary energy failure is critical, as it is the
optimal time for intervention strategies to ameliorate cell death. As apoptosis and
necrosis progress at a high rate, it is crucial to rescue cells within hours of the insult
otherwise the damage will become irreversible.

Apoptotic Mechanisms
Programmed cell death was first introduced in 1964 by Lockshin and colleagues.
They suggested that the cell death occurring during development may not be a
spontaneous or accidental event but instead, an intricate sequence of controlled processes
leading to self-destruction (Lockshin et al. , 1965). The term apoptosis was then first
brought in 1972 by Kerr and colleagues, where they used to describe the morphological
processes leading to self-destruction (Kerr et al. , 1972). Apoptosis is an important
process during development and is involved in differentiation,
proliferation/homoeostasis, regulation and function of the immune system as well as
removal of harmful cells (Fadel et al. , 1999).
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The morphological features of an apoptotic cell are shrinkage of the cell,
chromatin condensation, blebbing and finally fragmentation into small structures called,
‘apoptotic bodies’. Necrosis, on the other hand, results in the cell bursting and releasing
its contents into the cells’ environment thus inducing a strong inflammatory response
(Leist et al. , 2001). Apoptosis is more prominent in less severe insults and is a delayed
event associated with activation of caspase cascades, thus being a potential therapeutic
target, whereas necrosis is more prevalent in severe HIE (Bonfoco et al. , 1995). In 2009,
Fatemi and colleagues (Fatemi et al. , 2009) showed that activation of caspase 3 in a
neonatal rodent model of HIE is prolonged and that it can persist for at least 7 days after
the insult.
Apoptotic pathways are intricate signaling mechanisms that have a variety of
players. A cell can undergo apoptosis via two major pathways: the extrinsic or the
intrinsic pathway. The extrinsic pathway, mainly mediated by death receptors, belongs to
the tumor necrosis factor receptor (TNFR) gene family. These receptors are located on
the cell surface and are triggered by their respective ligands to initiate apoptotic
signaling. However, a signal coming from an activated receptor may not generate a
strong enough signal to activate caspase cascades which are responsible for cell death.
Therefore, this signal may be amplified via the mitochondrial-dependent apoptotic
pathways by stimulating the pro-apoptotic Bcl-2 family members, Bax and Bak, which
eventually result in caspase 3 activation leading to cell death (Fatemi et al. , 2009).
The intrinsic signaling pathway mainly acts on the inside of the cell by disruption
of mitochondrial membrane potential causing the release of pro-apoptotic mediators into
the cytoplasm and is triggered by DNA damage and oxidative stress (Bernardi et al. ,
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1999; Loeffler et al. , 2000; Wang et al. , 2001) which triggers the caspase cascade. In
addition to the release of mitochondrial factors, cell homeostasis is disrupted which
results in activation of redox molecules such as NADH, NADPH and accumulation of
reactive oxygen species (ROS) triggering inflammatory responses. Although necrosis
may prevail in severe HIE cases, apoptosis is a good target for therapeutics due to its
delayed response and the potential target window that it presents.
Many studies of animal models of HIE have shown that during the period after the
injury many neurons die via activation of the pro-apoptotic protein, caspase-3. The
expression of caspase 3 was shown to be very prolonged, which indicates a prolonged
role of apoptosis after injury (Nakajima et al. , 2000). During this time, neurons can
either die or survive over the next few days to weeks which gives ideal time for possible
intervention strategies to preserve these neurons. Clinical studies that analyzed the
cingulate gyrus of infants who either died from severe birth asphyxia with HIE or from
sudden intrauterine death showed a significant number of apoptotic cells (Edwards et al. ,
1999). Caspases are proenzymes containing 3 subunits that cleave proteins in a specific
way that represent the morphological features of an apoptotic cell (Banasiak et al. ,
2000). Caspase 3 is a widely studied caspase that plays a major role in neuronal death
(Banasiak et al. , 2000). In newborn piglets subjected to HIE, apoptotic cell death was
detected morphologically and via DNA fragmentation 48h after the insult (Mehmet et al,
1994). In a rat model, apoptotic cell injury began between 6-24h after HI (Chen et al. ,
2003). In addition, brains from postmortem infants that suffered HIE were examined and
discovered high levels of caspase 3 (Rossiter et al. , 2002). Up to date, intervening at the
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caspase level thus inhibiting caspase 3 has been the most common intervention following
ischemia.

Inflammatory Mechanisms
Hypoxia ischemia triggers an inflammatory reaction that progresses for days to
weeks and plays a role in secondary brain injury. Inflammation is complex process
associated with the production and release of hundreds of signaling molecules such as
cytokines, chemokines and ROS which are highly induced after ischemia in the neonatal
brain (Szaflarski et al. , 1995; Hagberg et al. , 1996; Ivacko et al. , 1997; Barone et al. ,
1999; Cowell et al. , 2002). Cytokines have been implicated as important players in the
pathogenesis of HIE and may represent a final common pathway of brain injury. This has
been shown in animal studies, where levels of IL-1β were significantly upregulated after
HI injury (Aly et al. , 2006; Liu et al. , 2013; Li et al. , 2014). However, details regarding
the mechanisms or involvement of other cytokines in this process remains unclear.
Additionally, there are several other factors that are induced after ischemia such as
adhesion molecules (Frijns et al. , 2002), nitric oxide synthase (Forster et al. , 1999) and
cyclooxygenase-1 (Nogawa et al. , 1997).
Interleukins (ILs) such as TNFα, IL-6, IL-1β, IL-8 and tumor necrosis factors
released after an HI insult are major pro-inflammatory cytokines that play a role in
inflammatory processes and contribute to HI damage (Grow et al. , 2002). The
inflammatory genes are evident as early as 8h after insult and further increased from 24
to 72h post HI. Several studies have shown a correlation between injury and elevated
levels of cytokine/inflammatory response. Patients with HIE have been shown to have

7

elevated levels of inflammatory cytokines and are associated with later development of
cerebral palsy (Dammann et al. , 2008). Elevated levels of IL-6 and IL-8 have been
observed in the CSF of newborns which were correlated with exacerbated HIE and poor
neurodevelopmental outcome (Savman et al. , 1998). It has also been reported that HIE
patients have a significantly higher expression of cytokine concentrations (Shalak et al. ,
2002). A cohort study of full term infants that experienced perinatal asphyxia revealed
increased levels of IL-1β, IL-6 and TNFα when compared to normal infants (FosterBarber et al. , 2001). Those levels were observed in infants that either died at 1 year or
went on to develop cerebral palsy. Another clinical study, using blood collected from the
umbilical cord of infants that experienced asphyxia, revealed a 375-fold higher
concentration of IL-6 in those patients that developed HIE. Thus, indicating that the
immature brain is highly susceptible to the consequences of an inflammatory response
(Anthony et al. , 1997; Bona et al. , 1999) making inflammation a prominent player in the
pathogenesis of neonatal brain injury.
In mice animal studies, that underwent unilateral carotid artery ligation, it was
shown a significant increase in inflammatory genes in the injured hemisphere after the
insult (Bona et al. , 1999). IL-1β and TNFα are early response cytokines that are
synthesized and released by microglia, astrocytes and neurons. Some of their features
include the release of other cytokines, induction of leukocytes, influence of glial
expression and stimulation of trophic factors (Szaflarski et al. , 1995). A study showed
that when recombinant IL-1β receptor antagonist was administered it attenuated brain
damage caused by HI in rats (Martin et al. , 1994; Hagberg et al. , 1996) which is an
indicator that IL-1β plays a role in brain damage after HI. In 1995, Szaflarski and
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colleagues demonstrated for the first time that ischemic insult stimulates cytokine
production in the developing brain (Szaflarski et al. , 1995). In an HI rat model, IL-1β
mRNA levels were significantly increased at 4h after HI. Furthermore, IL-1β triggers
production of IL-6 which then acts together in response to HI. Another pro-inflammatory
inhibitor, simvastatin was used as pretreatment for HIE and showed a reduction in
expression of IL-1β and TNFα (Balduini et al. , 2004). Microglial activation, due to
injury caused to the brain, secretes pro-inflammatory cytokines, extracellular proteases,
and oxidative species, which damage surrounding tissue. This, in turn, stimulates a
further release of pro-inflammatory mediators thus exacerbating the damage after HIE
(Ivacko et al. , 1997; Yang et al. , 2015). Hence, targeting inflammatory response is
critical to ameliorate HI induced injury.
Several studies have achieved neuroprotection against ischemia by intervening
with inflammatory mediator’s function. For example, inhibition of either IL-1, TNFα or
adhesion molecules conferred neuroprotection after ischemia (Relton et al. , 1992;
Loddick et al. , 1996; Connolly et al. , 1997). Interleukins seem to play a major role in
HIE progression as mice deficient in IL-18 or inhibition of IL-1 decreased CNS
vulnerability to HI (Martin et al. , 1994; Hagberg et al. , 1996). Moreover, administration
of the anti-inflammatory cytokine, IL-10 reduced HI insult (Mesples et al. , 2003).

Oxidative Stress
Before birth, the fetus is in a low oxygen environment however, in the first few
minutes after birth, there is an abrupt increase in O 2 levels (80-90%) creating pro-oxidant
conditions to facilitate metabolic processes. In the event of pathological conditions, such
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as after hypoxic ischemic (HI) insult, a serious of deleterious events occur such as excess
calcium influx leading to oxidative stress (Allen et al. , 2011; Cao et al. , 2014; Zeeshan
et al. , 2016). In animal models, it was reported to be a significant accumulation of H 2O2
in neonatal mice after HI but not in adult (Lafemina et al. , 2006). Decrease in oxygen in
the newborn triggers a serious of events and the release of oxidases, NOS while
simultaneously reducing anti-oxidant enzymes triggers a massive upregulation of ROS. A
major target of ROS is the mitochondria, and the immature brain is especially susceptible
to that because of its poor scavenging system. When the ROS exceeds the mitochondrial
capacity, the resulting oxidative stress ruptures the mitochondrial membrane allowing the
release of proteins with the potential to trigger inflammatory cascades that lead to
apoptosis (Blomgren et al. , 2006; Nakai 2007).

Clinical Presentation and Therapeutic Strategies
Certain signs may appear shortly after birth such as organ dysfunction mainly the
heart, lungs, kidneys and liver which is a good indicator of possible HIE. In severe cases,
60% of the patients will develop seizures in the first 24h (Vasquez-Vivar et al. , 2017).
Other evident symptoms include arched back, breathlessness, lethargy and some nausea
and vomiting. Other symptoms that may be presented by the infant are difficulties
suckling, eating, swallowing and excessive drooling. In other cases, symptoms might not
be evident at the time of birth but might become apparent later in life at the toddler ages.
A child with birth injury may present symptoms later in life such as delay in motor skills,
lack of muscle control, speech problems, learning difficulties and general loss of motor
and learning abilities (Millar et al. , 2017).
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Current treatment modalities for HIE include anticonvulsants, hypothermic treatments
and fluid and electrolyte management, but despite the success of some of these, about 3050% of the patients will still develop serious long-term complications (Zanelli et al. ,
2011). The serious lack of understanding HI pathology, timing of therapeutic window and
lack of mechanistic studies has made it crucial to investigate novel therapeutic
approaches. It is imperative to understand the physiological cascades triggered by HI.

Hypoxic Ischemic Injury and Endoplasmic Reticulum Stress
The endoplasmic reticulum (ER), located in the cytoplasm, serves multiple
functions in maintaining cell homeostasis. One of its major functions is protein synthesis,
correct folding, modification and transportation of proteins. The ER lumen is an oxidative
environment crucial for proper folding of proteins and formation of disulfide bonds. As
its main role in protein folding and transport, it also contains chaperones responsible for
the control of these proteins. Many disturbances and stresses, such as ischemic events,
oxidative stress, calcium disturbances and inhibition of protein glycosylation, can alter
ER’s functions causing an accumulation of unfolded proteins. When the amount of
unfolded proteins exceeds the number of chaperones needed to refold these proteins it
causes ER stress (Xu et al. , 2005; Rissanen et al. , 2006). For cells to cope with this
stress they activate an evolutionary conserved response known as the unfolded protein
response (UPR). The initial intent of the UPR is to restore correct protein folding and
function and re-establish ER homeostasis. However, under prolonged stress, when these
adaptations fail, the ER initiates pro-apoptotic pathways thus triggering cell suicide
(Oyadomari et al. , 2004). The three major ER stress triggered apoptotic proteins are the
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inositol-requiring enzyme 1 (IRE1), the PKR-like ER kinase (PERK) and the activating
transcription factor-6 (ATF-6) (Korennykh et al. , 2009; Korennykh et al. , 2012).
The IRE1 contains both serine/threonine kinase domains and an endoribonuclease
domain. In mammals, IRE has been characterized to have two genes, IRE1α and IRE1β.
IRE1α is ubiquitously expressed in all tissues, whereas the IRE1β is only expressed
selectively in intestinal and respiratory epithelial cells (Martino et al. , 2013). The IRE1α
plays a critical role in splicing the X-box-binding protein 1 (XBP1) and has been
demonstrated in deletion studies to play a crucial role in murine embryonic development,
differentiation, function, and survival of many cell types which secrete large amounts of
protein (Wu et al. , 2015). Accumulation of unfolded proteins stimulates activation of
IRE1α and XBP1 splicing through its ribonuclease domain, which then translocates to the
nucleus and acts as a potent transcription factor of pro-apoptotic mediators (Hetz et al. ,
2011). In addition, it can also stimulate activation of Apoptotic signaling kinase-1
(ASK1) which causes downstream activation of stress kinases that promote apoptosis
(Ron et al. , 2008). Moreover, IRE1α also triggers pro-inflammatory responses in the ER
through direct binding with adaptor protein tumor necrosis factor alpha (TNFα) receptorassociated factor 2 (TRAF2) and subsequent activation of the nuclear factor-kappaβ (NFκβ) and c-Jun N-terminal kinase (JNK) pathways (Xu et al. , 2005; Cao et al. , 2014).
The second effector protein, PERK, once activated induces its
autophosphorylation and activates the kinase domain responsible for phosphorylating and
inactivating the eukaryotic translation initiation factor 2 subunit α (eIf2α) (Donnelly et al.
, 2013), thus shutting down the mRNA translation. PERK activation and phosphorylation
of eIF2a is linked with an increased translation of the mRNA encoding the initiation of
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activating transcription factor 4 (ATF4). The ATF4 is a transcription factor which
induces several genes involved in acid metabolism, antioxidant stress and protein
secretion (Rouschop et al. , 2010; Rzymski et al. , 2010). ATF4 can also induce the proapoptotic effector CCAAT/enhancer-binding homologous protein (CHOP), that activates
apoptosis (Oyadomari et al. , 2004; Jager et al. , 2012).
Finally, activation of ATF6 triggers a slightly different mechanism compared with
IRE1α and PERK. Accumulation of unfolded proteins activates ATF6 which causes it to
translocate from the ER membrane to the Golgi apparatus where proteases cleave it, thus
releasing it into the cytosol where it begins to regulate gene expressions causing an
increase in XBP1 levels (Yamamoto et al. , 2007).
Among the three UPR proteins, IRE1α is the key molecule responsible for cell
fate as there is evidence that it is the only protein that can directly bind to the misfolded
proteins and trigger a signaling response. Numerous studies show evidence that supports
this concept, including structural studies, protein interaction studies and peptide
interaction studies (Gardner et al. , 2011).

Apoptosis
The UPR is an important adaptive mechanism to protein misfolding, however,
prolonged ER stress leads to the activation of pro-apoptotic UPR signaling which plays a
critical role in pathological conditions. One of the major contributing proteins to
apoptosis that is activated as a result of ER stress is IREα. The IRE1α-XBP1 pathway is
required for normal development and function, however, increasing evidence suggests
that IRE1α may contribute to apoptotic cell death (Cao et al. , 2014). It can do so via

13

several different ways. First, it can activate the JNK pathway through direct interaction
with TRAF which inhibits Bcl-2 and hence inhibits its anti-apoptotic effects (Cao et al. ,
2014). Second, IRE1α may bind Bax and Bak on the ER membrane and initiate a
mitochondrial dependent cascade (Cao et al. , 2014). IRE1α has also been linked to
activation of two pro-apoptotic molecules, PUMA and BH3 (Cao et al. , 2014). More
recently, IRE1α has also been shown to degrade specific microRNAs that target caspase
2 and hence boosting caspase dependent apoptosis (Cao et al. , 2014).

Oxidative Stress
There are several ways the ER may cause reactive oxygen species (ROS)
production. Firstly, in the ER lumen the correct folding of proteins requires formation of
disulfide bonds to be able to stabilize tertiary and quaternary structures. Therefore, the
lumen has a highly oxidized environment which is needed for bond formation (Cao et al.
, 2014). Evidence suggests that oxidative protein folding is an important source of ROS
production (Cao et al. , 2014). ROS can be generated as a byproduct of protein folding,
mitochondrial respiration and detoxification.
Protein folding is catalyzed by oxidoreductases such as protein disulfide
isomerases (PDI). During bond formation, PDI transfers electrons to an acceptor to begin
another cycle of bond formation. The acceptor then transfers these electrons to molecular
oxygen and produces H2O2, which is major ROS produced in the ER lumen. Another
inducer of ROS production is NADPH oxidase 4 (Nox4). Nox 4 can physically interact
with PDI causing an increase in ROS generation. Studies have shown that under stress
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Nox4 levels are increased and at the same time ROS generation is also increased
(Zeeshan et al. , 2016).
It has been reported that ROS production results mainly from three ER-electron
coupling systems such as PDI and ERO1α, intra ER-GSSG/GSH and the NADPH-450
Reductase – Cytochrome P450 (NPR-CYP) complex. However, the majority ROS
produced in the ER is from the microsomal monooxygenase (MMO) system which is
composed of the NPR-CYP complex. It is responsible for the production of superoxide
anion radicals and H2O2. The leakage of electrons during electron transfer between NPR
to CYP plays an important role in ROS generation. Increased P4502E1, a member of the
CYP family, protein activity and expression has been linked with ROS generation and
reported in several animal models (Kim et al. , 2009; Henke et al. , 2011). Inhibitors of
P4502E1 have shown protection against ethanol-induced hepatic injury (Gouillon et al. ,
2000). As a result, P4502E1 activation has led to increased levels of ROS. Further
research is required to examine its mechanisms, but it is evident that liver injury and
insulin resistance both involve P4502E1. Another potent suppressor of P4502E1
expression was shown to be Bax Inhibitor-1 (BI-1). Kim and colleagues showed that in
the presence of BI-1, the levels of P4502E1 were significantly reduced thus ameliorating
ER stress induced ROS accumulation in in vitro experiments using Neo cells (Kim et al. ,
2009).
ROS may also be generated via release of calcium from the ER. This causes an
increase in mitochondrial calcium which alters metabolism and eventually causes ROS
production (Gorlach et al. , 2006). Increase in ROS overloads the mitochondria and
stimulates it to work faster thus consuming more oxygen. An increase in oxygen
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consumption will activate nitric oxide synthase which will then inhibit the activity of
complex IV further increasing ROS production (Xu et al. , 2004; Murphy 2009; Meares
et al. , 2011).

Inflammation
ER stress can contribute to a wide variety of inflammatory processes. In the CNS,
ER stress may induce inflammation which can produce interferon-gamma and apoptosis
can occur as a direct result (Zhang et al. , 2008). ER stress is also observed in the lungs
where it is associated with increase in CHOP and subsequent ROS accumulation and
cell death (Endo et al. , 2006). During ER stress, there is also a release of calcium which
activates inflammasomes through an inositol triphosphate (IP 3)-mediated mechanism that
releases the calcium stored in the ER, resulting in accumulation of ROS (Zeeshan et al. ,
2016). In addition, the accumulation of misfolded proteins has been linked with
inflammatory processes in bowel disease and many autoimmune diseases (Garg et al. ,
2012). Hence, targeting inflammation with anti-inflammatory drugs has shown promise
against ER stress induced injury (Yamazaki et al. , 2006).
The UPR may also initiate inflammatory cascades thus triggering proinflammatory protein signaling. These include NF-kβ and MAPKs. In studies, they were
triggered from eIF2 phosphorylation from PERK signaling, as depressing mRNA
translation caused decreased levels of NF-kβ in cytosol (Lin et al. , 2007; Lin et al. ,
2013; Lin et al. , 2014). Another UPR protein involved in inflammatory responses is
IRE1α. It can recruit the inflammatory marker, TRAF2, which can then couple IRE1α
activation with various inflammatory pathways (Cao et al. , 2014).
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In addition to inflammatory responses from UPR proteins, there are other
signaling pathways that respond to ER stress and induce inflammation. ER stress and
inflammation are connected via several pathways such as ROS, release of calcium,
activation of NF-kβ and MAPK. It is well known that ROS are important mediators to
inflammation (Raha et al. , 2000).
Correct protein folding in the ER is an energy consuming mechanism and highly
oxidative process. During formation of disulfide bonds, to manufacture tertiary and
quaternary protein structures, there is a large amount of electron flow and utilization of
oxygen, which produces ROS (Tu et al. , 2002). Therefore, an increase in protein folding
in the ER is corelated with ROS production and subsequent inflammation. Moreover,
during ER stress, there is a release of calcium into the cell which causes depolarization of
mitochondrial membrane, thus disrupting electron transport resulting in ROS. This cycle
of calcium release, ROS production and accumulation of misfolded proteins work in
conjunction to activate pathways that lead to inflammation (Malhotra et al. , 2007; Zhang
et al. , 2008).

Endoplasmic Reticulum Stress Suppressors
The Transmembrane Bax Inhibitor-1 (TMBIM) Protein Super Family
The Bax Inhibitor-1 (BI-1) is an evolutionary conserved protein which is part of
the TMBIM protein family involved in cytoprotection. Members of this protein family
are hydrophobic in nature and hence reside on the ER membrane, Golgi or plasma
membrane. The TMBIM family are composed of five highly conserved orthologues of
BI-1 which are referred to as TMBIM family of proteins, BI-1 family or Lifeguard

17

family: GRINA/TMBIM3 (glutamate receptor ionotropic NMDA protein 1), BI1/TMBIM6, TMBIM2/Lfg/FAIM2, GHITM/TMBIM5 (growth hormone-inducible
transmembrane protein), RECS1/TMBIM1 (responsive to centrifugal force and shear
stress gene 1 protein) and GAAP/TMBIM4 (Golgi antiapoptotic-associated protein)
(Zhou et al. , 2008; Rojas-Rivera et al. , 2015).
Among these proteins, it has been reported that BI-1/TMBIM6, GRINA/Lfg-1,
Lfg-2/FAIM2 and Lfg-4/GAAP play a role in apoptosis (Hu et al. , 2009), however,
TMBIM6/BI-1 is the best described member of the family and has several reports of its
anti-apoptotic activities (Hu et al. , 2009; Rojas-Rivera et al. , 2015).

Bax Inhibitor-1 (BI-1/TMBIM6) Protein Family
The BI-1 is an evolutionary conserved protein first discovered in yeast and seen to
be widely expressed in tissues such as the heart, lungs, liver, stomach, colon, kidney,
brain, placenta, skeletal muscle and pancreas (Xu et al. , 1998; Grzmil et al. , 2006). It
has been observed that BI-1’s levels vary in these organs during various stages of life.
For example, BI-1 was shown to peak during times of high apoptosis (Jean et al. , 1999;
Chae et al. , 2004), thus indicating a possible link between BI-1 and cell death.
BI-1 contains six alpha-helix transmembrane domains with both of its N and C
terminus exposed to the cytosol. Its protective role has been mapped to its C terminus, as
deletion studies of the C terminus abrogated BI-1’s ability to suppress Bax induced cell
death in yeast (Kawai-Yamada et al. , 2004).
It was named as Bax Inhibitor-1 due to its functional effect to suppress cell death
via inhibition of Bax gene but not because of a direct physical interaction with Bax (Xu et
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al. , 1998). There are several studies that show evidence of BI-1’s ability to regulate the
intrinsic pathways but not the Fas and TNFα induced extrinsic pathways. It was reported
that overexpression of BI-1 in interleukin-3 dependent pro-B lymphocytes attenuated
apoptosis induced from intrinsic pathway inhibitors (Xu et al. , 1998). Transfection of BI1’s antisense induced apoptosis in human embryonic kidney cells regardless of the
stressors (Xu et al. , 1998). Additionally, it was reported that BI-1’s effects are caspase
independent, as administering tunicamycin to BI-1 overexpressing cells in the presence of
a caspase inhibitor did not cause translocation of Bax to mitochondria (Chae et al. ,
2004). However, when BI-1 overexpressing cells were treated with staurosporine with the
caspase inhibitor, it showed translocation of Bax to mitochondria (Chae et al. , 2004).
This indicates that BI-1’s anti-apoptotic activity is more sensitive to ER stress inducing
agents (Robinson et al. , 2011).

Bax Inhibitor-1 Like Proteins
TMBIM1 or Lifeguard 3. The TMBIM1 is also known as Lifeguard-3 (Lfg-3) or
RECS (Responsive to centrifugal force and shear). It is a seven helix transmembrane
protein localized to endosomal and lysosomal membranes and expressed in almost all
tissues (Hu et al. , 2009). It was shown to play a role in vascular remodeling as there
were no abnormalities in Lfg-3 knockout mice (Zhao et al. , 2006), however in aged
animals it caused aortic dilatation (Zhao et al. , 2006).
TMBIM2 or Lifeguard 2. TMBIM2 is also predicted to contain seven helix
transmembrane domain and is located in Golgi and ER. It is predominantly expressed in
nervous system (Schweitzer et al. , 1998), and specifically, in dendritic processes and
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synapses. In contrast to BI-1, TMBIM2 protects from cell death induced by the extrinsic
pathway, Fas, but not TNFα (Somia et al. , 1999; Fernandez et al. , 2007). It was reported
that inhibition of TMBIM6 with shRNA increased sensitivity of neural cells to Fas
induced cell death (Fernandez et al. , 2007).
TMBIM3 or Lifeguard 1. It was recently demonstrated that, like BI-1, TMBIM3
resides on the ER membrane and co-immunoprecipitation experiments revealed its
physical interaction with BI-1 (Rojas-Rivera et al. , 2015). Studies showed that knocking
down TMBIM-3 in BI-1 wild type cells did not cause spontaneous cell death, but in
contrast, knocking down TMBIM-3 in BI-1 knockout cells led to appearance of cell death
features (Rojas-Rivera et al. , 2012). ER stress may trigger upregulation of
TMBIM3/Lfg1 through PERK dependent mechanism (Hetz et al. , 2011). In conclusion,
TMBIM3 and TMBIM6 may have synergistic function for anti-apoptotic activity
however there is very little information regarding this protein and its signaling
mechanism is unclear.
TMBIM4 or Lifeguard 4. TMBIM4 is identified as a Golgi anti-apoptotic
protein and housekeeping gene (Lee et al. , 2007). It is widely expressed in tissues and
has shown close resemblance to BI-1. TMBIM4 can inhibit apoptosis triggered by
intrinsic and extrinsic stimuli (Gubser et al. , 2007) and can reduce calcium stores (de
Mattia et al. , 2009). It was shown that inhibition of Lfg-4 caused apoptosis and was seen
to also be upregulated in human breast cancer cells (van 't Veer et al. , 2002).
Lifeguard 5. Found predominantly in eutherian mammals and not in
invertebrates, Lifeguard 5 is predicted to have eight transmembrane helices (Hu et al. ,
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2009). It is reported as TMBIM1 because of its great resemblance. In mouse models, it is
expressed only in the adult testis (Hu et al. , 2009).

Bcl-2/Bcl-Xl
These proteins are also localized to the ER membrane and are protective against
ER stress. The main mechanism via which Bcl-2 works is believed to be through a
decrease in ER levels of calcium via IP3Rs.

MicroRNAs
New emerging data has shown that microRNAs may either modulate ER stress or
be activated by ER stress (Sano et al. , 2013). The PERK mediated activation of miR30c
is stimulated upon ER stress which is correlated with downregulation of XBP1 (Byrd et
al. , 2012). miR211 has also been identified as a PERK target that promotes cell survival.
It was reported that miR221 is associated with CHOP mediated apoptosis during ER
stress (Behrman et al. , 2011). As such, ER stress apoptosis was reported to be enhanced
by miR221mimics and attenuated by miR221 inhibitors. Additionally, it was illustrated
that CHOP regulates miR708 (Upton et al. , 2012) and spliced XBP1 was necessary for
stress associated miR346 induction which regulate immune responses.

Bax Inhibitor-1 and Endoplasmic Reticulum Stress
BI-1 as a Regulator of Apoptosis
As the ER is responsible for correct protein folding and maturation of proteins as
well as a regulation of calcium, any unfavorable environment may disrupt the ER
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function inducing ER stress and the UPR. The main function of the UPR is to allow cells
to adapt to different stresses. In the event that this is not resolved, and the stress is
prolonged it will result in calcium release, promoting apoptosis and pro-apoptotic ER
signaling.
Reports show evidence of BI-1’s protective effects in cell culture experiments
where, cells overexpressing BI-1 that were challenged with ER stress inducers, or during
OGD and ischemic reperfusion, did not show any characteristics of apoptotic changes
(Chae et al. , 2004). There was no caspase activation, no blebbing, no formation of
apoptotic bodies. Inversely, cells lacking BI-1 exhibited sensitivity to the same ER
stresses (Chae et al. , 2004). Thus BI-1 may aid to inhibit ER stress signaling pathways
(Chae et al. , 2004; Bailly-Maitre et al. , 2006).
BI-1 was shown to interfere with all three ER signaling pathways, in particular, it
was shown to be able to physically bind to IRE1α thereby blocking its RNase activity
(Lisbona et al. , 2009). BI-1 overexpressing cells showed a decrease in levels of IRE1α as
well as its downstream factor XBP1 (Lee et al. , 2007). BI-1 was reported to suppress
IRE1α activity by forming a complex in both fly and mouse models of ER stress (Sano et
al. , 2013). Knocking out TMBIM6 gene, responsible for BI-1 production, caused
hyperactivity of the IRE1α pathway, while cells overexpressing BI-1 showed to inhibit
IRE1α kinase and endoribonuclease activity. In addition, deletion of the C terminus of
BI-1 failed to bind to IRE1α and hence did not suppress IRE1α activity (Sano et al. ,
2013). Additionally, BI-1 deficiency also increased XBP1, a major downstream effector
of IRE1α. In mice knockout studies, it was shown that mice were viable and developed
normally despite a deficiency in TMBIM6/BI-1 (Sano et al. , 2013; Urra et al. , 2013).
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However, they were more susceptible to tissue injury induced by stroke, ischemiareperfusion and experimental ER stress in brain, liver and kidney (Sano et al. , 2013).
Although BI-1 was not shown to interact with PERK or ATF6, it still affected
their signaling pathways (Lee et al. , 2007). Lee and colleagues reported that eIF2α levels
decreased when BI-1 is overexpressed, indicating that it may block PERK pathway via
unknown mechanisms (Lee et al. , 2007). In addition, BI-1 was also shown to decrease
ATF6 cleavage thus also blocking its activity (Lee et al. , 2007).

BI-1 as a Regulator of Oxidative Stress and Inflammation
During times of stress, such as after HI insult, ROS production and accumulation
is significantly increased in the cell thus culminating in oxidative stress and the release of
ROS. This release of ROS surrounds tissue and causes damage, potentially promoting
inflammatory processes (Duval et al. , 2003; Kopprasch et al. , 2003).
The main source of ROS production in the ER is from the microsomal
monooxygenase (MMO) system composed of NADPH-P450 reductase (NPR) and the
cytochrome P450 (CYP) members (Nieto et al. , 2002; Robinson et al. , 2011).
Specifically, the CYP member, P4502E1, is known to produce significant amount of
ROS such as H2O2 (Nieto et al. , 2002).
It is now known that BI-1 may regulate ER stress induced ROS production via two
mechanisms. Firstly, it can influence Nuclear Factor Erythroid 2-Related Factor 2 (Nrf-2)
upregulation, which is a redox sensitive transcription factor that controls expression of
different anti-oxidant enzymes, such as heme oxygenase-1 (HO-1). Cells overexpressing
BI-1 were shown to increase Nrf-2 levels, and subsequently HO-1 levels, which blocked
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ROS (Lee et al. , 2007). Secondly, BI-1 can directly interact with NPR though its C
terminus, thus altering the electron flow between NPR-CYP and destabilizing this complex
resulting in blockage of ROS (Kim et al. , 2009). Co-immunoprecipitation studies have
revealed that BI-1 is in close proximity and has high affinity for NPR in vivo but to a lesser
extend for P4502E1 (Kim et al. , 2009; Watanabe et al. , 2009). However, BI-1 can regulate
P4502E1 activity, by binding to NPR and disrupting the flow of electrons between NPR
and CYP hence lowering P4502E1 activity and its ability to produce ROS (Kim et al. ,
2009; Yang et al. , 2010; Henke et al. , 2011). The C terminus of BI-1 is required for BI-1
to bind to NPR and hence to disrupt this complex. Adding an antibody raised against the
BI-1’s C-terminus or in a C terminus BI-1 mutant abrogated the inhibitory effect of BI-1
(Watanabe et al. , 2009; Li et al. , 2014). Other studies also showed that deletion of C
terminus of BI-1 had less inhibition of P4502E1 induced ROS production and there was
no NPR binding (Kim et al. , 2009; Watanabe et al. , 2009; Li et al. , 2014). Despite the
clear functional connection between BI-1 and P4502E1, a direct interaction of the two
proteins was not shown.

Specific Aims
Hypoxic-ischemic (HI) brain injury remains a leading cause of mortality and
morbidity for infants, affecting between 2-4 from 1000 full-term births, and nearly 60%
of premature infants (Vannucci et al. , 1997; Volpe 2001). Among survivors, 20-40%
develop significant neurological impairments, associated with life-long medical, social,
and emotional difficulties (Bracewell et al. , 2002; Ferriero 2004; van Handel et al. ,
2007; Zanelli et al. , 2011). Numerous attempts to reduce HI-induced consequences have
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failed in the clinical setting. In order to improve future outcomes, it is imperative to
explore different therapeutic targets to either amplify or replace current therapeutic
strategies.
Endoplasmic reticulum stress (ER) is a major pathology encountered after HI,
associated with dysregulation of protein folding with downstream effects on apoptosis
and inflammation which have been implicated in a variety of disease processes (Kaser et
al. , 2008; Li et al. , 2012; Chaudhari et al. , 2014; Li et al. , 2015; Yang et al. , 2015). HI
induced ER stress up-regulates several stress sensors’ signaling pathways, primarily, the
inositol requiring enzyme-1 alpha (IRE1α) signaling pathway (Madeo et al. , 2009; Sano
et al. , 2013). ER stress is also associated with reactive oxygen species (ROS)
accumulation, mainly from the NADPH-dependent cytochrome P450 reductase (NPR)
and P4502E1 (CYP) complex. CYP has been linked as one of the main players in ROS
generation (Kim et al. , 2009).
Bax-inhibitor 1 (BI-1) protein, mainly expressed on ER membrane, has been
shown to play a major role in inhibiting ER stress related apoptosis (Xu et al. , 1998;
Watanabe et al. , 2009) and inflammation. BI-1 is encoded by the TMBIM6 gene, part of
the Bcl-2 family of proteins that can directly bind to Bcl-2 and form a complex, resulting
in inhibition of pro-apoptotic molecules (Xu et al. , 1998; Watanabe et al. , 2009; Iwata et
al. , 2011; Robinson et al. , 2011). Evidence from previous in vitro studies supports BI1’s ability to directly bind to IRE1α and inhibit this pro-apoptotic signaling pathway
induced after ER stress (Chae et al. , 2004; Lisbona et al. , 2009; Bailly-Maitre et al. ,
2010). Furthermore, it has been shown that BI-1 can reduce ROS accumulation by
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disrupting the electron transport between NPR and CYP and by simultaneously activating
Nrf-2 (Lee et al. , 2007; Kim et al. , 2009; Henke et al. , 2011).
This proposal will be the first to show BI-1’s anti-apoptotic and antiinflammatory effects in an animal stroke model, by overexpression of the BI-1 protein
with intracerebroventricular (icv) injection of human adenoviral-TMBIM6 (AdTMBIM6) vector and elucidate the pathways associated with BI-1’s protective effects.
The specific objective of this proposal is to establish BI-1’s anti-apoptotic and
anti-inflammatory effects in an in vitro oxygen glucose deprivation (OGD) model, as
well as in an in vivo neonatal hypoxia ischemia (HI) rat model, followed by subsequent
clarification of the mechanisms via which it confers its protective properties. Our central
hypothesis is that (1) transfection of PC-12 cells with Ad-TMBIM6 vector will improve
cell viability after OGD (2) in vitro OGD model will help determine the major pathways
involved in BI-1’s protective effects (3) overexpression of the BI-1 protein in the brain,
via Ad-TMBIM6 injection will improve recovery after neonatal HI by reducing ER stress
induced (a) neuronal apoptosis via inhibition of IRE1α signaling pathway and (b)
oxidative stress induced inflammation via dissociation of the NPR-CYP complex and
subsequent inhibition of ROS. This hypothesis will be tested with the following specific
aims:

Aim 1
To determine whether BI-1 upregulation exerts its anti-apoptotic effects via the
IRE1α signaling pathway in an in vitro and in vivo neonatal HI rat model. This aim
will examine the effects of BI-1 overexpression on IRE1α and PERK signaling, as well as
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examine BI-1’s long-term effects on functional deficits after HI. ER stress, as a result of
HI injury, is reported to trigger three main signaling pathways: IRE1α, PERK and ATF6,
which under pathological conditions lead to apoptosis. Studies have shown that
overexpression of BI-1 in cells in response to ER stress inducers, or during OGD and I/R
injury, can attenuate ER stress induced apoptotic phenotypes. BI-1 knockout cells
showed the opposite effects, indicating that BI-1 aids to inhibit ER stress signaling
pathways (Chae et al. , 2004). BI-1 can also physically bind to and inhibit IRE1α (BaillyMaitre et al. , 2010) and its downstream molecules such as XBP1 (Lisbona et al. , 2009;
Bailly-Maitre et al. , 2010). Several in vitro studies have been done in TBI, MCAO and
hepatic ischemia/reperfusion models which present data in support of BI-1’s antiapoptotic effects (Bailly-Maitre et al. , 2006; Krajewska et al. , 2011; Ma et al. , 2014). It
is unclear whether BI-1 exerts its anti-apoptotic effect mainly via IRE1α inhibition or
whether it also plays a role in inhibiting PERK. This aim will help determine whether
IRE1α is the major pathway via which BI-1 exerts its neuroprotective role and translate
this in vitro finding to our in vivo studies.

Aim 2
To investigate the anti-oxidative effects of BI-1 overexpression and the signalling
pathways involved in an in vitro and in vivo neonatal HI rat model. This aim will
examine BI-1’s role in oxidative stress, focusing on BI-1’s ability to dissociate the NPRCYP complex and activate Nrf-2 transcription factor resulting in attenuation of ER stress
induced ROS accumulation and subsequent inflammation.
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The major source of ER stress induced ROS accumulation is from the microsomal
monooxygenase (MMO) system which is composed of cytochrome P4502E1 (CYP),
NADPH-P450 reductase (NPR) and some phospholipids (Kim et al. , 2009). The leakage
of the electron transfer between NPR and CYP results in the accumulation of ROS. Our
specific hypothesis is that BI-1 will reduce ER stress induced ROS accumulation and
subsequent inflammation via: (1) coupling with NPR and disrupting the NPR-CYP
complex; (2) upregulating the anti-oxidant transcription factor, Nrf-2, which leads to
increase in HO-1 production. HO-1 is a rate-limiting enzyme shown to be able to
attenuate ROS accumulation. Overexpression of BI-1 should increase HO-1, which
should subsequently decrease the UPR by limiting oxidative dysregulation of the ER.
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Figure 1.1 Schematic Representation of the central hypothesis and specific aims
Aim 1 will investigate the effects of overexpression of BI-1on the stress sensor protein,
IRE1α in HI model. The signaling pathway molecules will be measured as well as the
apoptotic markers in the brain and assess infarct area. Aim 2 will study the effects of
overexpression of BI-1 on the NPR-CYP complex, responsible for production of ROS, and
also measure the levels of anti-oxidant enzymes and inflammatory mediators.
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Abstract
A wide variety of conditions may contribute to oxidative protein folding
processes in the endoplasmic reticulum (ER) which cause ER stress. Three major
pathways, referred to as the unfolded protein response (UPR), transmit information
regarding protein folding status in the ER lumen to help cells cope with altered protein
synthesis demands. However, after hypoxic ischemic (HI) injury, prolonged activation of
the UPR triggers pro-apoptotic signaling causing cells to undergo apoptosis.
Here we identified Bax Inhibitor-1 (BI-1), an evolutionary protein encoded by the
Transmembrane Bax inhibitor Motif Containing 6 (TMBIM6) gene, as a novel modulator
of ER stress induced apoptosis after HI brain injury in a neonatal rat pup. BI-1 may
modulate the UPR response by a direct physical interaction with the stress sensor, IRE1α,
and via indirect inhibition of the PERK receptor. The main objective of our study is to
overexpress BI-1 using viral-mediated gene delivery of human adenoviral-TMBIM6 (AdTMBIM6) vector, to investigate its anti-apoptotic effects as well as elucidate its signaling
pathways in an in vitro oxygen glucose deprivation (OGD) model and in an in vivo
neonatal HI rat model.
Cells transfected with Ad-TMBIM6 vector improved cell viability, while
manipulation of both IRE1α and PERK determined IRE1α as the predominant pathway
via which BI-1 confers neuroprotection after OGD. Our in vivo data showed similar
results in ten-day old unsexed Sprague-Daley rat pups that underwent right common
carotid artery ligation followed by 1.5h of hypoxia. Rat pups injected with Ad-TMBIM6
vector showed a reduction in percent infarcted area and improved long-term neurological
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outcomes, as well as attenuated neuronal degeneration and reduced ER stress induced
neuronal apoptosis via inhibition of IRE1α signaling pathway.
This study showed a novel role for BI-1 and ER stress in the pathophysiology of
HI and provided a basis for BI-1 as a potential therapeutic target.
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Introduction
Hypoxic-ischemic (HI) brain injury is a result of hypoxemia or reduced cerebral
blood flow (Ferriero 2004) causing pulmonary immaturity, respiratory distress syndrome,
hypercapnia, hypo perfusion, seizures and long-term cognitive and behavioral deficits
(Wirrell et al. , 2001; Bracewell et al. , 2002; Ferriero 2004; Bartha et al. , 2007; Yang et
al. , 2015). HI affects 1-4 cases per 1000 births (Vannucci 2000) with morbidity rates
ranging between 10-80% based on the severity of injury (Kaser et al. , 2008; Chaudhari
et al. , 2014). Current treatments include hypothermia, anticonvulsants, fluid and
electrolytes management, and drugs such as atropine and epinephrine but (Zanelli et al. ,
2011; Jacobs et al. , 2013) despite the efficacy of some of the treatments, 40-50% of
treated patients still have persistent neurodevelopmental deficits (Barrett et al. , 2007;
Zanelli et al. , 2011).
The Endoplasmic reticulum (ER) is responsible for correct protein folding and
protein function (Zhang et al. , 2014). Protein folding is crucial for cell survival.
However, under pathological conditions, such as HI, there is an accumulation of unfolded
proteins beyond the capacity of the chaperons to fold the protein causing ER stress (Xu et
al. , 2005; Barrett et al. , 2007; Zhang et al. , 2014). This condition triggers the unfolded
protein response, resulting in the activation of pro-apoptotic cascades (Madeo et al. ,
2009; Sano et al. , 2013). The three transmembrane receptor pathways activated as a
result of ER stress are (1) Inositol-requiring protein 1 alpha (IRE1α), (2) RNA-dependent
protein kinase-like ER kinase (PERK) and (3) activating transcription factor 6 (ATF6)
(Sano et al. , 2013). The main function of these receptors is to alleviate stress and restore
normal cell function by reducing misfolded proteins. However, under prolonged ER
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stress, these pathways become over activated resulting in incorrect signalling, leading to
apoptosis (Tabas et al. , 2011). This is further exacerbated by subsequent reactive oxygen
species (ROS) accumulation.
The Bax-inhibitor 1 (BI-1) protein mainly resides in the ER membrane and is
encoded by the TMBIM6 gene (Xu et al. , 1998; Li et al. , 2014; Rojas-Rivera et al. ,
2015). BI-1 is part of the Bcl-2 family of proteins that regulates pro-apoptotic molecules
such as Bax by directly interacting with Bcl-2 as shown in in vivo experiments (Xu et al. ,
1998; Watanabe et al. , 2009; Iwata et al. , 2011). Studies have shown that cells
overexpressing BI-1, that have been under ER stress inducers, or during OGD and I/R
injury, did not show apoptotic phenotypes; whereas, BI-1 knockout cells showed the
opposite effects, indicating that BI-1 aids to inhibit ER stress signaling pathways (Chae et
al. , 2004). BI-1 can also physically bind to and inhibit IRE1α (Bailly-Maitre et al. ,
2010) and its downstream molecules such as XBP1 (Lisbona et al. , 2009; Bailly-Maitre
et al. , 2010). Several in vitro studies have been done in TBI, MCAO and hepatic
ischemia/reperfusion models which present data in support of BI-1’s anti-apoptotic
effects via inhibition of ER stress and the subsequent pro-apoptotic pathways (BaillyMaitre et al. , 2006; Krajewska et al. , 2011; Ma et al. , 2014).
It is unclear whether BI-1 exerts its anti-apoptotic effects mainly via IRE1α inhibition or
whether it also plays a role in inhibiting the PERK receptor; Using an in vitro oxygen
glucose deprivation (OGD) model, we sought to determine whether IRE1α is BI-1’s
major pathway which we can then translate to our in vivo model. Our specific objective is
to establish that overexpression of BI-1 protein, via administration of human adenoviralTMBIM6 (Ad-TMBIM6) vector, will attenuate the morphological and neurological
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consequences post neonatal HI by attenuation of ER stress induced pathways. Elucidating
BI-1’s mechanism in vitro and translating it to our in vivo HI model is crucial and will
help to provide a basis for BI-1 as a potential therapeutic target in clinics.

Materials and methods
In Vitro Experiments
Rat pheochromocytoma cells, PC-12 cells, were used at passage 6 through 9. Cells
were grown as previously described(Dickson et al. , 1986).

Oxygen Glucose Deprivation Model
Cells were replaced with glucose deprived media after which they were placed in
hypoxic chamber and flushed with 1% Oxygen for 1h, 1.5h, 3h, 5h and 6h. Complete
growth media was then added, and cells allowed to recover for 18h after which were
prepared for cell death assay and western blotting(Agani et al. , 2002; Souvenir et al. ,
2014).

Cell Death Assay
Assessed with trypan exclusion as previously described(Souvenir et al. , 2014).
Briefly, cells were scraped and then centrifuged for 5min after which they were resuspended in 10ml complete growth media. 20µl from cells was added to 20µl Trypan
blue and well mixed and let to sit for 3min. 10µl from mixture was placed on cell counter
slides, slides were then read using an automated cell counter. The average of 6 counts
was used (Souvenir et al. , 2011).
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Western Blotting for Cells
Cells were collected 18h after OGD and stored for western blotting as previously
described (Dominguez et al. , 2008; Souvenir et al. , 2014). Briefly, cells were
centrifuged and then re-suspended in 1ml PBS, after which they were centrifuged one
more time at 14000rpm for 5min. The supernatant was removed, leaving only the pellet.
RIPA was added with protease inhibitor and pipetted thoroughly until pellet was fully
broken down. It was then allowed to sit on ice for 20min following which it was
centrifuged for 30min. The supernatant was harvested, and the pellet was discarded.
Protein concentration was measured using Bradford assay and SD-PAGE electrophoresis
was performed as previously described(Dominguez et al. , 2008). Primary antibodies: BI1 antibody (1:100, Abcam), anti-IRE1α antibody (1:100, Abcam), Anti-PERK antibody
(1:100, Abcam) and Casp3/cleaved caspase 3 antibodies (1:400, cell signaling
technology).

Calculation of MOI
To determine the total amount of infectious particles needed to infect one cell,
Multiplicity of Infection (MOI), was calculated as follows: #cells * desired MOI= total
PFU (or Plaque Forming Units) needed; (total PFU needed) / (PFU/ml) = total ml of
virus needed to reach desired dose.

Transfections
siRNA transfection: Prior to transfection, cells were differentiated and allowed to
reach 80% confluency in poly D-lysine coated 6 well plates. siRNA was prepared
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according to manufacturer’s protocol (Sigma-Aldrich); a stock of 10uM siRNA was
prepared, 4ul from siRNA stock were mixed with 125µl Opti-MEM. In a separate tube,
7µl liofectamine3000 was mixed with 125µl Opti-Mem. The two tubes were combined
and left to sit in room temperature for 15-45min. 250µl mixture/well was applied to cells
and an additional 1ml Opti-MEM was added. Cells were then placed in an incubator for
5-7h, following which media was removed and replaced with normal growth media.
CRISPR transfection: 50,000 cells were plated and allowed to grow and
differentiate following which cells were transfected first with Ad-TMBIM6, then 700µl
CRISPR was added 48h later. Plasmid was diluted in 200µl sterile DNase free water
(provided) giving a concentration of 0.1µg/µl (Santa Cruz). Stock solution was further
diluted with transfection medium to bring to desired concentration of 2µg-8µg per
500,000 to 1 million cells. After transfection cells were placed in incubator for 5-7h
following which media was removed and replaced with normal media and prepared for
OGD.
STF-083010 (IRE1α antagonist), CCT020312 (PERK agonist) and APY-29 (IRE1α
agonist) transfection: dissolved and prepared according to manufacturer
recommendations. STF-083010 was prepared to final concentration at 20µM or 60µM,
CCT020312 was tested at 10µM and APY-29 was tested at 20µM and 60µM. Best dose
was chosen at 20µM for both drugs (cell viability quantification data not shown).

In Vivo Experiments
The Institutional Animal Care and Use Committee of Loma Linda University has
approved all protocols. The animals were cared for and all studies conducted in

55

accordance with the United States Public Health Service's Policy on Humane Care and
Use of Laboratory Animals. Sprague Dawley rat mothers, with litters of 10~12 pups,
were purchased from Harlan Labs (Livermore, CA). The following have been applied to
ensure robust and unbiased experimental design and analysis of data, (A) Randomization
& Blinding: All animals were randomly assigned to experimental groups via generation
of random number assignment. Furthermore, all investigators were blinded to animal
groups and the interventions that animals received. (B) Control Groups: Appropriate
control groups were included for each intervention group. Furthermore, for siRNA
experiments, animals were injected only siRNA or scramble, without treatment (AdTMBIM6) as control. No animals were excluded apart from the normal 12% mortality
rates for this model.

Hypoxic Ischemic Rat Model
HI surgery was performed using the established Rice Vannucci model as
previously described (Vannucci et al. , 1997; Vannucci et al. , 2004). Briefly, P10
unsexed Sprague-Daley rat pups were placed into a temperature-controlled chamber for
induction of general anesthesia. The animals were anesthetized with 3% isoflurane gas in
air and maintained at 2.5% isoflurane in air during surgery. Throughout the surgical and
postoperative period, temperature was controlled with heating blankets and incubators.
After induction of anesthesia the neck of the rats was prepared and draped using standard
sterile techniques. Next a small midline neck incision on the anterior neck was made
with a No. 11 blade surgical knife (approximately 3-5 mm in length). Using gentle blunt
dissection, the right carotid artery was isolated and gently separated from surrounding
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structures. The carotid artery was then ligated with 5-O surgical suture. After the carotid
artery had been ligated, the skin was sutured. Rats were then allowed to recover for 1h on
a heated blanket. Thereafter, they were placed in a 500-ml airtight jar partially submerged
in a 37 °C water bath to maintain a constant thermal environment. Rat pups were
exposed to a gas mixture of 8% Oxygen and 92% Nitrogen for 90min. Thereafter, the
animals were returned to their mothers and monitored daily.

Drug Administration
Human adenoviral TMBIM6 vector (Ad-TMBIM6) (Vector Biolabs) was injected
intracerebroventricularly (icv) at 2µl containing 1.6x1011 PFU/ml or 1.7x1011 PFU/ml per
injection(Bailly-Maitre et al. , 2010) at 72h, 48h and 24h pre-HI, as well as 1h post HI.
BI-1 siRNA (Sigma-Aldrich) and IREα CRISPR activation plasmid (AP) (Santa Cruz)
were administered icv at 48h pre-HI.

Infection Area Calculation
Animals were euthanized at 72h post HI and infarct area was assessed using
2,3,5-Triphenyltetrazolium Chloride Monohydrate (TTC) staining. Briefly, brains were
sectioned into 2mm slices and placed in TTC stain as previously described(Zhou et al. ,
2009; Li et al. , 2012). Red is indicative of live tissue.

Behavioral Analysis
Neurobehavior test were performed at 4 weeks using rotarod, water maze and foot
fault. We chose these neurobehavioral tests because they effectively cover a range of
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neurological functioning (sensation, motor function, and cognitive functioning). In
addition, these tests have a good predictive value of impaired neurological function. The
water maze test has been closely correlated with long-term functional deficits. Animals
were then euthanized, and brain samples weighed and collected for histopathological
examination.
Foot Fault: Animals were placed on a horizontal grid floor (square size 28 x 3
cm, wire diameter 0.4 cm) for 2 min. Foot-fault is defined as when the animal
inaccurately places a hindlimb, and it falls through one of the openings in the grid. The
numbers of foot-faults for each limb of each animal was recorded (Hartman et al. , 2005;
Bouet et al. , 2010).
Rotarod: The rotarod assesses motor impairment. Animals were placed on a
spinning bar to test their motor function. Rats underwent stationary, constant and 5rpm
acceleration which was recorded by (Hartman et al. , 2005; Bouet et al. , 2010).
Water Maze: Morris water maze test assesses learning, memory, and visual
functions (Hartman et al. , 2005; Bouet et al. , 2010). Activity of animal’s swim paths
were recorded and measured for quantification of distance, latency, and swimming speed
for 5 days using the Video Tracking System SMART-2000 (San Diego Instruments Inc.,
CA). Animals were then sacrificed, and brains collected for histological analysis.

Western Blotting of Brain Tissue
Western blotting was performed as previously described (Li et al. , 2015). Equal
amounts of protein (30μg) was loaded on an 8%~12% SDS-PAGE gel and
electrophoresed, it was then transferred to a nitrocellulose membrane (0.2μm). The
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membrane was blocked for 1h and then incubated with primary antibodies overnight at
4°C: BI-1 antibody (1:100, Abcam), anti-IRE1α/anti-pIRE1α antibodies (1:100, Abcam),
Anti-XBP1 antibody (1:100, Abcam), anti-Chop antibody (1:500, Proteintech),
Casp3/cleaved caspase 3 antibodies (1:400, cell signaling technology), anti-Bcl2 (1:500,
Abcam), anti-bax (1:500, Abcam) and anti-ROMO1 antibody (1:100, Abcam). The
membranes were then incubated at room temperature for 1h with horseradish peroxidaseconjugated secondary antibodies (Santa Cruz Biotechnology) followed by
chemiluminescence detection (GE Healthcare). The densitometric quantification of the
bands was performed with image J software.

Histology
Brains were post-fixed in formalin, and then sectioned into 10μm thick coronal
slices by cryostat (CM3050S; Leica Microsystems) for immunohistochemistry, FlouroJade C and into 16-20μm thickness for Nissl’s staining.
Immunofluorescence staining: Rats were anesthetized at 72h post HI and
transcardially perfused with PBS and formalin. Brain sections were then post fixated with
formalin for 1 day and dehydrated in 30% sucrose solution. Immunofluorescence staining
was performed as previously described(Shi et al. , 2017). The tissue mounted on the
slides were washed with 0.1M PBS three times for 5min then incubated in 0.3% Triton
X-100 in 0.1M PBS for 30min at room temperature. This was then washed with 0.1M
PBS for 5min, 3 times, and primary antibodies were applied overnight at 4°C: anti-BI-1
antibody (1:100, Abcam), anti-IRE1α antibody (1:100, Abcam), NeuN ((1:100, Abcam),
and CC3 (1:100, Abcam) respectively. After washing with PBS, sections were incubated
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with appropriate secondary antibodies: anti-rabbit IgG-TR, anti-mouse IgG-FITC, antigoat IgG-FITC, anti-rabbit IgG-FITC (1:200) for 1h @ RT. Finally, slides were covered
with DAPI and visualized under a fluorescent microscope and a Magna Fire SP system
(Olympus) was used to analyze microphotographs.
Fluoro-Jade C: 10μm brain sections were cut with cryostat (Leica LM3050S) for
Fluoro-Jade C as previously described(Xie et al. , 2017). Slides were immersed in 1%
sodium hydroxide dissolved in 80% ethanol for 5min, followed by being rinsed for 2min
in 70% ethanol, then 2min in distilled water. Slides were then incubated in 0.06%
potassium permanganate solution for 10 min, followed by 2min in distilled water, and
then transferred into 0.0001% solution of Fluoro-Jade C (Millipore, USA) which was
dissolved in 0.1% acetic acid. Slides were then rinsed 3 times with distilled water for
1min. After the water was drained and slides dried, they were cleared in xylene for 1min,
and finally cover slipped with DPX (Sigma-Aldrich, USA).
Nissl’s staining and evaluation of brain tissue loss and ventricular area: Pups were
euthanized at 4weeks post HI and brains were sectioned. The prepared slides (16 μm)
were dehydrated in 95% and 70% ethanol for 1min respectively, rinsed in tap water and
distilled water for 30sec. The slides were then stained with 0.5% cresyl violet (SigmaAldrich, USA) for 2min, and washed in distilled water for 10 and 30sec. 100% ethanol
and xylene were used to dehydrate the tissue sections 2 times for 1.5min before placing a
coverslip with permount on the slide (Shi et al. , 2017). Image J was used to measure
percent tissue loss.
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Statistical Analysis
Rats were randomly assigned to each group and the investigators were blinded from
previous procedures. All values will be presented as mean ± standard deviation (SD),
and analyzed by one-way analysis of variances (ANOVA), followed by Tukey test or
Holm-Sidak or Dunnett’s post hoc analysis. A P-value less than 5% will be considered
significant. Sample sizes were determined by power of 0.8, α=0.05, and a 20% standard
deviation from the preliminary results. The estimated sample size was 4 to 9/group.

Results
To Establish the Optimum Time for OGD and Optimal Multiplicity of Infection
(MOI) Needed of Ad-TMBIM6 Vector to Successfully Transfect PC12 Cells
Data showed a time dependent decrease in percent cell viability in cultured PC12
cells when exposed to variable periods of OGD. Cells were exposed to 5 different OGD
time periods ranging from 1h to 6h. Percent cell viability was significantly reduced when
compared to control at 3h, 5h and 6h (Figure 2.1A). Optimal time for OGD exposure was
chosen at the 3h time point to best represent severity of our in vivo HI model.
Optimal Multiplicity of Infection (MOI) was shown to be 100MOI as it significantly
improved cell viability compared to vehicle and to 200/1000MOI after 3h OGD (Figure
2.1B).
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To Determine the Effect of Ad-TMBIM6 on Percent Cell Viability in an in vitro
OGD Model
Cells exposed to 3h of OGD (Vehicle) showed a significantly higher percent of cell
death when compared to control and OGD+ Ad-TMBIM6 group (Figure 2.1C-D). BI-1
siRNA (a BI-1 inhibitor), APY-29 (20µM; IRE1α agonist) or CCT020312 (PERK
agonist) reversed BI-1’s protective effects as seen from the significantly lower percentage
of cell viability (Figure 2.1D). Ad-TMBIM6+PERK CRISPR(knockdown) did not
improve cell viability when compared to OGD group. On the contrary, adding STF083010 (IRE1α antagonist; 20µM) to Ad-TMBIM6 showed to significantly improved cell
viability (~85% living cells) when compared to PERK CRISPR or OGD (~40% living
cells) group.
Control groups, OGD+Ad-TMBIM6+scramble/or DMSO/or control CRISPR showed to
significantly improve cell viability when compared to Vehicle group/or APY-29/or
CCT020312/or PERK CRISPR but did not restore cell viability up to control or AdTMBIM6 treated group levels.
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Figure 2.1 Percent cell viability significantly improved after transfection of cells with
100MOI of Ad-TMBIM6 in an in vitro OGD Model
Time dependent decrease was seen in percent cell viability in cultured PC12 cells when
exposed to 1h, 1.5, 3h, 5h and 6h in OGD. Percent cell viability was significantly reduced
when compared to control at 3h, 5h and 6h (A). Cells transfected with 100MOI
significantly improved percent cell viability when compared to vehicle or to 200MOI and
1000MOI at 3h of OGD (B). Representative picture showing cell morphology and density
of cells after OGD in all groups (C). Cell death assay showed that Ad-TMBIM6 treatment
group as well as the control groups (Ad-TMBIM6+scramble siRNA; AdTMBIM6+DMSO and Ad-TMBIM6+control CRISPR) and Ad-TMBIM6+STF-083010
significantly improved cell viability when compared to vehicle, BI-1 siRNA, APY-29,
CCT020312 and PERK CRISPR knockdown groups (D). (Data expressed as mean +/−
SD; *p<0.05 vs control; #p<0.05 vs vehicle; @p<0.05 vs Ad-TMBIM6 and scramble
siRNA or vs 100MOI; ε p<0.05 vs Ad-TMBIM6 only; $p<0.05 vs BI-1 siRNA; &p<0.05
vs APY-29; +p<0.05 vs DMSO; %p<0.05 vs CCT020312; ^p<0.05 vs STF-083010 and
Control CRISPR. n=5-6/group using one-way ANOVA followed by Tukey multiplecomparison post hoc analysis).
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To Establish BI-1’s Anti-Apoptotic Effects via the IRE1α Signaling Pathway in
an in vitro OGD Model
To test the underlying mechanism via which BI-1 attenuated apoptosis both IRE1α
agonist (APY-29) and antagonist (STF-083010) were used as well as PERK agonist
(CCT020312) and antagonist (PERK CRISPR knockdown). These helped to manipulate
both pathways to determine the dominant one. Quantification data showed that BI-1
expression levels were significantly increased in the Ad-TMBIM6 treated group and in
the control groups: scramble siRNA, DMSO and Control CRISPR; while BI-1 siRNA
and APY-29 showed to reverse those effects (Figure 2.2A-B). CCT020312 and PERK
CRISPR as well as STF-083010 showed similar expression levels of BI-1 to AdTMBIM6 treatment group (Figure 2.2A-B).
Intervening at the PERK receptor did not seem to alter BI-1 expression levels as
CCT020312 did not show to affect BI-1 levels whereas intervening at IRE1α with APY29 significantly reduced BI-1’s levels (Figure 2.2B). Ad-TMBIM6, scramble siRNA +
Ad-TMBIM6, DMSO + Ad-TMBIM6 and Control CRISPR significantly reduced
pIRE1α, pPERK and cleaved caspase 3 (CC3) expression levels (Figure 2.2C-E)
compared to vehicle. Meanwhile, BI-1 siRNA, APY-29, CCT020312 and PERK CRISPR
showed to increase pIRE1α expression levels (Figure 2.2C). Expression levels of pPERK
were significantly upregulated after OGD in vehicle group, BI-1 siRNA and CCT020312
when compared to the rest of the groups (Figure 2.2D). While Ad-TMBIM6 and control
groups (scramble siRNA, DMSO and Control CRISPR) significantly reduced CC3
expression, activation of PERK with CCT020312 did not significantly upregulate CC3
when compared to treatment or control groups (Figure 2.2E), in fact it showed to
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significantly decrease CC3 expression levels. Furthermore, APY-29 showed to
significantly upregulate CC3 when compared to CCT020312. In addition, STF-083010
showed to be more effective at reducing CC3 compared to PERK CRISPR (Figure 2.2E).
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Figure 2.2 BI-1 exerted its anti-apoptotic effects via inhibition of IRE1α in an in vitro
OGD model
Representative picture of western blot bands showing protein expression levels (A).
Quantification data of bands showed that BI-1 expression levels were significantly
increased in the Ad-TMBIM6 treatment group and in the control groups (scramble siRNA,
DMSO and Control CRISPR), while BI-1 siRNA and APY-29 groups reversed those
effects (B). Ad-TMBIM6 and control groups significantly reduced pIRE1α, pPERK and
CC3 expression levels (C-E). BI-1 siRNA, APY-29, CCT020312 and PERK CRISPR
increased pIRE1α expression levels (C). Expression levels of pPERK were significantly
upregulated in vehicle, BI-1 siRNA and CCT020312 compared to the rest of the groups.
PERK CRISPR effectively knocked down pPERK expression levels (D). Ad-TMBIM6 and
control groups significantly reduced CC3 expression levels, activation of PERK with
CCT020312 did not significantly upregulate CC3 when compared to treatment or control
groups (E). APY-29 showed to significantly upregulate CC3 when compared to
CCT020312. In addition, STF-083010 was more effective at reducing CC3 compared to
PERK CRISPR (E). (Data represent +/− SD; *p<0.05 vs control; #p<0.05 vs vehicle;
@p<0.05 vs Ad-TMBIM6 and Ad-TMBIM6+scramble siRNA; $p<0.05 vs BI-1 siRNA;
&p<0.05 vs APY-29; +p<0.05 DMSO; %p<0.05 vs CCT020312; ^p<0.05 vs STF-083010
and Control CRISPR. n=5-6/group using one-way ANOVA followed by Tukey multiplecomparison post hoc analysis).
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Expression Levels of Endogenous BI-1, IRE1α, XBP1 and CHOP in Time
Dependent Manner post HI
BI-1 expression levels increased in a time dependent manner, which peaked at 24h
and then significantly decreased to sham levels at 72h post HI (Figure 2.3A-B). IRE1α
and XBP1 expression levels significantly increased at 6h post HI and remained elevated
until 72h post HI (Figure 2.3A, C-D). CHOP levels significantly increased at 24h post HI
when compared to sham (Figure 2.3A, E).

Low Dose Ad-TMBIM6 Administered at 48h pre-HI Reduced Infarct Area at
72h post HI
To test the best time of administration of Ad-TMBIM6 vector we tested 4 time points.
Ad-TMBIM6 significantly reduced infarct area compared to vehicle treated group when
it was administered at 48h pre-HI (Figure 2.3F). Furthermore, to evaluate dose response
of Ad-TMBIM6 viral vector on infarct area two doses were used (1) low dose of
1.6x1011PFU/ml and (2) a high dose of 1.7x1011PFU/ml. TTC staining results showed
that the optimal dose for administration of the viral vector was the low dose
(1.6x1011PFU/ml) as it proved to be more effective as it significantly reduced infarct area
when compared to vehicle or high dose vector (Figure 2.3G).
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Figure 2.3 To Measure expression levels of endogenous BI-1, IRE1α, XBP1 and
CHOP and determine optimum time and dose of Ad-TMBIM6 administration post
HI
Representative pictures of Western blot bands (A). Data showed that BI-1 expression levels
significantly increased in a time-dependent manner from 6h to 24h, and then dropped to
sham levels at 72h post HI (B). IRE1α inceased significantly post HI compared to sham
and remained elevated untill 72h post HI (C). The expression of XBP1 increased post HI
and remained elevated from 6h through 72h post HI (D). CHOP levels increased from 6h
to 72h, peaking at 24h post HI (E). Data expressed as mean +/- SD; *p<0.05 vs sham; #
p<0.05 vs 6h, @ p < 0.05 vs 24h; n=4, using one-way ANOVA followed by Tukey
multiple-comparison post hoc analysis. Optimal time of injection was at 48h pre-HI, at this
time significantly reduced the percentage of infarcted area versus vehicle, or the other time
points (F). Low dose of Ad-TMBIM6 (1.6x1011 PFU) viral vector significantly improved
the percentage of infarcted area when compared to vehicle or high dose (1.7x1011 PFU)
vector (G). (Data expressed as mean +/- SD; *p<0.05 vs sham; # p<0.05 vs vehicle, @ p <
0.05 vs Ad-TMBIM6 (1.6x1011 PFU), n=6, using Unpaired T-Test for (F) and one-way
ANOVA followed by Tukey multiple-comparison post hoc analysis for (G)). Blots were
cropped to improve clarity.
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Histological Staining at 72h post HI
Immunofluorescence staining showed a significantly higher expression of BI-1 on
neurons in the Ad-TMBIM6 treatment group when compared to vehicle (Figure 2.4A).
Furthermore, IRE1α was significantly decreased in the Ad-TMBIM6 treatment group
when compared to vehicle, but also showed co-localization with neurons (Figure 2.4B).
In addition, staining for BI-1 on astrocytes demonstrated minimal colocalization in all
groups (Figure 2.4C). (Green was for neuronal/astrocyte staining, Red was for BI1/IRE1α staining and Blue was for DAPI. Merge showed the colocalization of BI-1 or
IRE1α on neurons/astrocytes. Scale bar = 50 μm; n=1/group).
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Figure 2.4 Histological staining showed co-localization of BI-1 on neurons but not
with astrocytes at 72h post HI
Immunofluorescence staining demonstrated a significantly higher expression of BI-1 on
neurons in Ad-TMBIM6 treatment group compared to sham or vehicle (A). Fluorescent
levels of IRE1α was reduced in Ad-TMBIM6 treatment group when compared to vehicle
(B). (Green was for neuronal staining, Red was for BI-1 or IRE1α staining and Blue was
for DAPI). Merge showed the colocalization of BI-1 or IRE1α on neurons (A-B). (Scale
bar = 50 μm; n=1/group). There was minimal co-localization of BI-1 with astrocytes (C).
(Green was for astrocyte staining, Red was for BI-1 and Blue was for DAPI). Merge
showed the colocalization of BI-1 on astrocytes (C). (Scale bar = 50 μm; n=1/group).
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Ad-TMBIM6 Improved Long-term Neurological Function at 4weeks post HI
To test the effects of Ad-TMBIM6 treatment on the long-term neurological
impairments induced by neonatal HI, neurological function was assessed by foot fault,
rotarod and water maze at 4weeks post HI. In all three behavioral tests, vehicle group
performed significantly worse compared to sham. Ad-TMBIM6 treatment group
significantly improved sensorimotor coordination as assessed by the fewer number of
foot faults (Figure 2.5A) and longer distance covered on the rotarod test (Figure 2.5B)
versus vehicle. In the water maze test, compared to sham group, vehicle group
demonstrated substantial loss of memory and learning abilities in terms of the time it took
to reach the platform (Figure 2.5C) as well as the distance travelled to find the platform
(Figure 2.5D).
However, Ad-TMBIM6 showed to significantly improve both memory and learning
function when compared to vehicle (Figure 2.5C-D). Administration of Ad-TMBIM6
significantly reduced brain atrophy as seen from the percentage of brain weights (Figure
2.5E). Nissl’s staining demonstrated that Ad-TMBIM6 can attenuate percent brain tissue
loss (Figure 2.5F).
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Figure 2.5 Ad-TMBIM6 improved long term neurological deficits when assessed
at 4 weeks post HI
Ad-TMBIM6 improved long-term motor deficits as seen from the significantly lower
number of foot faults (A) and the longer distance traveled on the rotating rod (B) in the
Ad-TMBIM6 treatment group when compared to vehicle. Long-term learning and memory
were significantly improved in Ad-TMBIM6 group compared to vehicle (C-D). Percent of
ipsilateral/contralateral brain weights were significantly improved in Ad-TMBIM6 group
when compared to vehicle (E). Nissl staining of brains demonstrated a significant lower
percentage of tissue loss in Ad-TMBIM6 group compared to vehicle (F). (Data expressed
as mean +/- SD; *p＜0.05 vs sham; #p＜0.05 vs vehicle; n=6-9 using one-way ANOVA
followed by Tukey multiple-comparison/or Holm-Sidak post hoc analysis).
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BI-1 siRNA and IRE1α CRISPR Activation Plasmid Reversed Ad-TMBIM6
Protective Effects at 72h post HI
To evaluate whether pathway interventions can affect apoptosis and increase infarcted
area, we used a BI-1 inhibitor (BI-1 siRNA) and a IRE1α activator (IRE1α CRISPR
Activation Plasmid (AP)). Results demonstrated that Ad-TMBIM6+BI-1siRNA group
significantly reversed BI-1’s protective effects, as did Ad-TMBIM6+IRE1α CRISPR AP
group, as seen from the significant increase in infarcted area when compared to AdTMBIM6 only group (Figure 2.6A-B). Both control groups, scramble siRNA and control
CRISPR AP, did not exacerbate the damage when compared to Ad-TMBIM6 treated
group. Furthermore, BI-1 siRNA only group (without treatment) further exacerbated the
injuries when compared to Ad-TMBIM6 treatment group.
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Figure 2.6 The effects of BI-1 siRNA and IRE1α CRISPR activation plasmid on
infarct area at 72h Post HI
The percentage of infarcted area was significantly increased in vehicle, BI-1siRNA and
IRE1α CRISPR activation group when compared to Ad-TMBIM6 and their respective
control groups (A-B). Representative schematic for mechanism study (C). (Data expressed
as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05 vs Ad-TMBIM6;
$p<0.05 vs BI-1 siRNA; +p<0.05 vs Ad-TMBIM6+scramble siRNA; &p<0.05 vs IRE1α
CRISPR AP; %p<0.05 vs control CRISPR. n=6/group using one-way ANOVA followed
by Tukey multiple-comparison post hoc analysis).
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BI-1 Exerted its Neuroprotective Effects via the IRE1α/XBP1/CHOP pathway
at 72h post HI
To test the underlying mechanism via which BI-1 attenuated apoptosis the following
groups were used: sham, vehicle, Ad-TMBIM6, Ad-TMBIM6+BI-1siRNA, AdTMBIM6+scramble siRNA, Ad-TMBIM6+IRE1α CRISPR AP, AD-TMBIM6+ control
CRISPR, BI-1siRNA only and scramble siRNA only groups. Quantification data
demonstrated that BI-1 expression levels were significantly increased in the Ad-TMBIM6
treatment group, Ad-TMBIM6+scramble siRNA and in the Ad-TMBIM6+control
CRISPR groups; while BI-1 siRNA and IRE1α CRISPR AP groups reversed those effects
(Figure 2.7A-B). BI-1 siRNA only and scramble siRNA only groups showed similar
expression levels of BI-1 as vehicle. Ad-TMBIM6 significantly reduced expression of
pIRE1α, XBP1, CHOP and ROMO1 (a modulator that induces production of ROS);
while BI-1-siRNA and IRE1α CRISPR AP reversed BI-1’s protective effects which
demonstrated elevated expression of pro-apoptotic pathway proteins (Figure 2.7A, C-F).
No significant difference was observed in total IRE1α expression levels
(quantification data not shown). Immunohistochemistry demonstrated that siRNA
reduced expression of BI-1 in all three cell types (Figure 2.7G).
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Figure 2.7 BI-1 exerted its protective effects via the IRE1α/XBP1/CHOP pathway at
72h post HI
Representative picture of western blot data (A). Quantification of bands demonstrated
that Ad-TMBIM6 as well as control groups (Ad-TMBIM6+scramble siRNA and AdTMBIM6+CRISPR Control) significantly increased BI-1 expression levels in the brain
when compared to vehicle or sham. While, BI-1 siRNA and IRE1α CRISPR AP
significantly reversed those effects. Furthermore, BI-1 siRNA only group also reduced BI1’s expression levels (B). Data showed that pIRE1α, XBP1, CHOP and ROMO1
expression levels were significantly elevated in vehicle, BI-1 siRNA and IRE1α CRISPR
AP groups whereas Ad-TMBIM6 and control groups reversed those effects (C-F) at 72h
post HI. (Data expressed as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05
vs Ad-TMBIM6; $p<0.05 vs BI-1 siRNA; +p<0.05 vs Ad-TMBIM6+scramble siRNA;
&p<0.05 vs IRE1α CRISPR AP; %p<0.05 vs control CRISPR; ^p<0.05 vs Ad-TMBIM6+
BI-1 siRNA; ε p<0.05 vs BI-1 siRNA only group. n=6/group using one-way ANOVA
followed by Tukey multiple-comparison post hoc analysis). Immunofluorescent staining
shows the effects of siRNA on neurons, astrocytes and microglia (G) (Scale bar = 50 μm;
n=1/group).
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Overexpression of BI-1 Suppressed Pro-Apoptotic Protein Markers and
Attenuated Neuronal Apoptosis at 72h post HI
To evaluate whether over expression of BI-1 with Ad-TMBIM6 could attenuate
apoptosis, western blot was done to quantify Bcl-2, Bax, Cleaved Caspase 3 (CC3) and
Caspase 3.The data demonstrated that Ad-TMBIM6 treatment group can significantly
upregulate anti-apoptotic marker, Bcl-2 (Figure 2.8A-B), while it attenuated expression
of pro-apoptotic markers, Bax and CC3 (Figure 2.8A, C-D). In addition, administration
of BI-1 si-RNA and IRE1α CRISPR AP reversed Ad-TMBIM6’s protective effects; it
significantly upregulated pro-apoptotic markers (Bax and CC3) and downregulated the
anti-apoptotic marker, Bcl-2 (Figure 2.8A-D). There was no significant difference in total
Caspase 3 expression levels (quantification data not shown).
Since HI results in neuronal degeneration and apoptosis, we stained for CC3 and used
Flouro-Jade C staining to test Ad-TMBIM6’s neuroprotective effects. Immunoflourescent
staining showed higher expression and co-localization of CC3 on neurons in vehicle
group compared to sham or Ad-TMBIM6 groups. (Figure 2.8E; Scale bar 100µm). Green
Flouro-Jade C staining showed more positively stained neurons undergoing apoptosis in
vehicle group compared to sham or Ad-TMBIM6 treatment group (Figure 2.8F; Scale bar
100µm).
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Figure 2.8 Overexpression of BI-1 attenuated apoptosis at 72h post HI
Representative picture of western blot data showing bands of the expression levels of Bcl2, Bax and CC3 (A). Western blot data quantification of bands showed that Ad-TMBIM6
significantly increased Bcl-2 expression levels compared to vehicle or sham (B). AdTMBIM6 significantly reduced Bax and CC3 at 72h post HI compared to vehicle while BI1 siRNA and IRE1α CRISPR AP intervention groups reversed those effects (C-D). (Data
expressed as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05 vs AdTMBIM6; $p<0.05 vs BI-1 siRNA; +p<0.05 vs Ad-TMBIM6+scramble siRNA; &p<0.05
vs IRE1α CRISPR AP; %p<0.05 vs control CRISPR. n=6/group using one-way ANOVA
followed by Tukey multiple-comparison/Holm-Sidak/Dunnett’s post hoc analysis).
Fluorescent staining showed more positively CC3 stained neurons in vehicle group
compared to sham or Ad-TMBIM6 treated group (E). (Scale bar 100µm; n=1/group).
Fluoro-Jade C staining showed more positively stained neurons undergoing apoptosis in
vehicle group compared to sham or Ad-TMBIM6 treatment group (F). (Scale bar 100µm;
n=1/group).
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Discussion
Understanding cellular and molecular mechanisms can lead to a more effective
therapies needed to ameliorate the long-term deficits after Hypoxic-Ischemic (HI) injury
(Volpe 2001; Bracewell et al. , 2002; van Handel et al. , 2007). Bax Inhibitor-1 (BI-1) is
a promising target for therapeutic use, however little is known about its signaling
mechanism which limits its clinical translation. Given the lack of effective treatment
options for neonatal HI injury, this study focused on identifying a novel role for BI-1
protein and Endoplasmic Reticulum (ER) stress in the pathophysiology of neonatal HI.
Hopefully, this new understanding can be leveraged to design interventions that
positively affect the outcome of HI patients.
One of the three main pathways triggered after ER stress, main pathology
encountered post HI injury, is IRE1α; a key molecule responsible for cell fate, as it can
directly bind to the misfolded proteins, unlike PERK or ATF6 (Gardner et al. , 2011;
Sano et al. , 2013). Accumulation of unfolded proteins stimulates autophosphorylation of
IRE1α’s kinase domain, which then activates the RNase to splice X-box-binding protein
1 (XBP1). This acts as a potent transcription factor that triggers pro-apoptotic signaling
mechanisms. PERK also contributes to ER stress by attenuating mRNA translation thus
inhibiting protein synthesis (Sano et al. , 2013). We focused on IRE1α and PERK, as they
are the major receptors that contribute to ER stress induced cell death.
BI-1 has been characterized in various insults as a pro-survival protein in ER
stress (Chae et al. , 2004; Bailly-Maitre et al. , 2006; Lee et al. , 2007; Lisbona et al. ,
2009; Bailly-Maitre et al. , 2010; Castillo et al. , 2011; Robinson et al. , 2011). BI-1’s
anti-apoptotic effects were first described in cultured cells and in vivo mice model (Chae
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et al. , 2004; Bailly-Maitre et al. , 2006; Krajewska et al. , 2011; Ma et al. , 2014). It has
been reported to directly bind to and inhibit IRE1α (Lisbona et al. , 2009) by abolishing
its endoribonuclease activity (Castillo et al. , 2011). BI-1’s protective effects were further
reported in db/db mice where BI-1 protected mice from obesity associated insulin
resistance due to suppression of IRE1α (Bailly-Maitre et al. , 2010). Some evidence
showed that BI-1 may also indirectly inhibit PERK signaling pathway (Lee et al. , 2007),
however, other reports have shown that eIF2α phosphorylation, downstream of PERK,
was unaltered with BI-1 knockout mice (Bailly-Maitre et al. , 2006).
BI-1 has been found to be a potent inhibitor of ER stress induced pathways,
however the exact mechanism via which it may exert its pro-survival signaling remains
unknown. In this study we investigated the role of BI-1 on ER stress-induced apoptosis,
and we further elucidated BI-1’s main signaling pathway. As BI-1 has been shown to
inhibit IRE1α and to some extend PERK (Lee et al. , 2007; Robinson et al. , 2011), we
sought to investigate their involvement and to identify the dominant factor by using an in
vitro oxygen glucose deprivation (OGD) model. PC12 cells were transfected with (1) BI1 siRNA, IRE1α agonist (APY-29) and antagonist (STF-083010) in combination with
human adenoviral TMBIM6 (Ad-TMBIM6; gene responsible for expressing BI-1)
(Bailly-Maitre et al. , 2010) vector to test the role of the IRE1α signaling pathway and (2)
PERK CRIPSR knockdown and the CCT020312 (PERK agonist) together with AdTMBIM6 to test the involvement of the PERK signaling pathway. Cell viability data
indicated that Ad-TMBIM6 increased the percentage of viable cells versus cells that
underwent 3h OGD without Ad-TMBIM6 (Vehicle) (Figure 2.1C-D). Furthermore, BI-1
siRNA and APY-29 significantly reversed Ad-TMBIM6s protective effects (Figure
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2.1D). Activation of PERK with CCT020312 decreased the percentage of viable cells
compared to Ad-TMBIM6. However, double inhibition of PERK with AdTMBIM6+PERK CRISPR yielded a low cell viability count (~40%), which may suggest
that PERK may not play a major role in BI-1’s protective effects. On the contrary, double
inhibition of IRE1α with Ad-TMBIM6+STF-083010 improved cell viability to ~85%
versus ~40% in Vehicle and the PERK CRISPR group (Figure 2.1D). This data indicated
that manipulation of IRE1α may play a greater role than PERK signaling in BI-1’s
protective effects.
In support of our cell viability data, western blot results indicated that AdTMBIM6 or double inhibition of IRE1α with Ad-TMBIM6+ STF-083010, successfully
upregulated BI-1’s expression levels in PC12 cells and inhibited pIRE1α (Figure 2.2AC). However, inhibiting BI-1 with siRNA and activating IRE1α with APY-29,
significantly reversed those effects as seen from the decreased expression level of BI-1
(Figure 2.2B). Activation of IRE1α with APY-29 significantly reduced BI-1 and
increased pIRE1α, however, either activation of PERK with CCT020312 or inhibition
with PERK CRISPR did not alter BI-1’s nor pIRE1α expression levels (Figure 2.2B-C),
indicating that BI-1 is more influenced by IRE1α as opposed to PERK. While, APY-29
significantly increased the pro-apoptotic marker, CC3, CCT020312 did not show
significant CC3 upregulation (Figure 2.2E). Furthermore, double inhibition of IRE1α
with Ad-TMBIM6+STF-080310 further reduced CC3 versus double inhibition of PERK
with Ad-TMBIM6+PERK CRISPR, indicating that BI-1 may more potently attenuate
apoptosis via inhibition of IRE1α.
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Summary of our in vitro findings showed that either activating or inhibiting
PERK did not change BI-1’s expression levels versus Ad-TMBIM6, whereas
manipulation of the IRE1α receptor showed changes in BI-1. In addition, Ad-TMBIM6
successfully attenuated pIRE1α expression while inhibition of BI-1 reversed those effects
(Figure 2.2C). Based on these findings, we can conclude that despite BI-1’s inhibitory
effects on pPERK expression (Figure 2.2D), the effect isn’t prominent enough to confer
neuroprotection as seen from the CC3 levels (Figure 2.2E). Taken all the above together,
we believe that although BI-1 may have some inhibitory effects on PERK, its major
pathway operates via inhibition of IRE1α signaling.
We then hypothesized that intracerebroventricular injection of Ad-TMBIM6
vector would overexpress BI-1 and provide protection in an in vivo neonatal HI model via
inhibition of IRE1α singling. This hypothesis stems from our in vitro data as well as from
previous reports on BI-1’s anti-apoptotic effects via inhibition of IRE1α, causing
disruption of the receptors interaction with downstream pro-apoptotic molecules (XBP1
and CHOP) (Bailly-Maitre et al. , 2006; Lisbona et al. , 2009; Bailly-Maitre et al. ,
2010).
Expression of BI-1 may begin within 24-72h of injection, therefore we
administered Ad-TMBIM6 vector at multiple time points and sacrificed animals at 72h
post HI to determine the optimal time needed for the virus to replicate and begin
overexpressing BI-1(Bailly-Maitre et al. , 2010). Our results indicated that administration
of Ad-TMBIM6 vector at 48h pre-HI significantly reduced the percentage of infarcted
area at 72h post HI and was chosen as the optimal time (Figure 2.3F). In addition, a low
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dose viral vector (1.6x1011 PFU) was more protective then the higher dosage (1.7x1011
PFU) (Figure 2.3G).
To evaluate whether Ad-TMBIM6 attenuated neuronal apoptosis we performed
Flouro-Jade C (FJC) staining, which stains for degenerating neurons (Figure 2.8F). AdTMBIM6 vector reduced the number of FJC positively stained neurons, indicating
attenuation of apoptosis. To further confirm BI-1’s anti-apoptotic effects, we stained for
CC3 on neurons and saw that Ad-TMBIM6 was able to attenuate the expression of CC3
as well as reduce co-localization with neurons which is indicative of less neuronal death
(Figure 2.8E).
To determine a delay in acquisition of neurobehavioral milestones and the effects
of Ad-TMBIM6 treatment post HI, neurocognitive outcomes were measured at 4
weeks using the Morris water maze, rotarod and foot fault tests. Results showed that AdTMBIM6 significantly improved motor and learning deficits (Figure 2.5A-D).
Furthermore, brain weight measurement and Nissl staining showed a significantly lower
percentage of tissue loss in the Ad-TMBIM6 group compared to vehicle (Figure 2.5E-F),
which is representative of our behavior findings.
Finally, to determine that BI-1 confers protection via inhibition of IRE1α, we
used a BI-1 siRNA to inhibit BI-1 and an IRE1α CRISPR activation plasmid (AP) to
counteract BI-1’s effects as depicted in the schematic in figure 2.6C. From our WB
results, we demonstrated that inhibition of BI-1 with siRNA, or activation of IRE1α with
CRISPR AP, significantly reduced BI-1’s expression levels (Figure 2.7A-B) and
increased pro-apoptotic markers (Figure 2.8 C-D). On the contrary, administration of AdTMBIM6 significantly increased BI-1 levels in the brain, attenuated pIRE1α, XBP1
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CHOP and reduced pro-apoptotic markers via inhibition of IRE1α (Figure 2.7 and 2.8).
To determine siRNA’s effects on different cell types we stained for neurons, astrocytes
and microglia. Results demonstrated a reduction in BI-1 expression in all three cell types
after administration of siRNA (Figure 2.7G) versus Ad-TMBIM6 treated groups (Figure
2.4A, C).
The ER dictates the fate of proteins, while the level of redox mediators modulates
the level of reactive oxygen species (ROS) (Cao et al. , 2014; Zeeshan et al. , 2016).
Persistent ER stress causes accumulation of misfolded proteins, which then triggers
IRE1α activation and further upregulation of CHOP. Increased levels of CHOP further
exacerbate cell death signaling through oxidative stress, which also contributes to ROS
generation (Cao et al. , 2014; Zeeshan et al. , 2016). Herein, we used a ROS marker,
Reactive-Oxygen-Species-Modulator-1 (ROMO1), which is protein coding gene
responsible for increasing ROS in cells. Western blot data demonstrated a significant
reduction in ROMO1 levels in the brain after Ad-TMBIM6 (Figure 2.7F). These results
were confirmed to be via BI-,1 as either BI-1 inhibition with siRNA, or over activation of
IRE1α with CRISPR AP in the presence of Ad-TMBIM6, reversed those effects.
In summary, overexpression of BI-1 attenuated apoptosis and improved
neurological outcomes post HI. The main novelty lies in successfully identifying BI-1’s
protective role and signaling pathway in ER stress induced apoptosis post neonatal HI.
This work is essential as it provides critical information that may be used to develop
more beneficial clinical treatments for HI patients, as well as provide a foundation for
future research in other diseases with similar pathologies.
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Abstract
Oxidative stress, inflammation and Endoplasmic Reticulum (ER) stress play a
major role in the pathogenesis of hypoxic ischemic (HI) injury in the neonate. ER stress
results in accumulation of unfolded proteins that trigger the NADPH-P450 reductase
(NPR) and the microsomal monooxygenase system which is composed of cytochrome
P450 members (CYP) generating reactive oxygen species (ROS) as well as the release of
inflammatory cytokines.
We explored the role of Bax Inhibitor-1 (BI-1) protein encoded by the
Transmembrane Bax inhibitor Motif Containing 6 (TMBIM6) gene, in protection from
ER stress after HI brain injury. BI-1 may regulate ER stress induced ROS production and
release of inflammatory mediators via two main mechanisms. Firstly, BI-1 can directly
bind to NPR, thus disrupting the NPR-CYP complex; and secondly, ROS production is
also controlled by the redox sensitive transcription factor, Nrf-2, which controls
expression of different anti-oxidant enzymes such as HO-1. BI-1 can upregulate Nrf-2,
promoting an increase in anti-oxidant enzymes, thus reducing ROS. Therefore, in this
study we evaluated BI-1’s inhibitory effects on ROS and inflammation by overexpressing
BI-1 in 10-day old unsexed Sprague-Dawley rat pups that underwent right carotid
ligation, followed by 1.5h of hypoxia using adenoviral mediated gene delivery of
TMBIM6.
Overexpression of BI-1 significantly reduced the percentage of infarcted area;
while silencing BI-1 reversed those effects. BI-1’s mediated protection was observed to
be via inhibition of P4502E1, a major contributor to ROS generation, as seen from the
decreased levels of P4502E1 and upregulation of Nrf-2 and HO-1, which correlated with
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a decrease in ROS and inflammatory markers. This effect was reversed with BI-1 or Nrf2 silencing. This study showed a novel role for BI-1 to inhibit a major regulator of ROS
production. Inhibition of P4502E1, together with activation of Nrf-2, demonstrates that
BI-1 has a great promise as a therapeutic target.
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Introduction
Hypoxia Ischemia (HI) in the perinatal period is associated with long-term
disabilities in children affecting 1-4 infants per 1000 births (Vannucci 2000). The most
common cause of HI is intrauterine asphyxia, which may be brought on by several factors
such as placental artery clotting, abruption or inflammatory processes (Fatemi et al. ,
2009). These result in diminished supply of blood and oxygen to the neonatal brain. In
the event of prolonged abruption and extended period of HI the neonate develops hypoxic
ischemic encephalopathy (HIE), causing irreversible brain injury (Fatemi et al. , 2009).
Despite the significant research progress identifying many molecular mechanisms for
neonatal HIE, therapeutic interventions are limited (Ferriero 2004; Gunn et al. , 2008;
Shankaran 2008).
One of the main contributing injury mechanism post HI is the disruption of
correct protein folding, that subsequently triggers reactive oxygen species (ROS)
accumulation, followed by activation of microglia, ultimately causing inflammation
(Ferriero 2004; Khwaja et al. , 2008). Inflammatory cytokine release has been associated
with HIE and has been shown to be significantly elevated in the full-term infant, which is
linked with further exacerbating the damage and results in poor neurodevelopmental
outcome (Fatemi et al. , 2009). Therefore, inhibition of inflammation post HI is an
attractive target for new therapeutic strategies.
Correct folding of transmembrane proteins takes place in the endoplasmic
reticulum (ER) which is composed of an elaborate system of chaperones and enzymes to
aid in this process(Stahl et al. , 2013). However, under stressful conditions, such as after
a hypoxic ischemic event, the number of proteins to be folded exceeds the capacity of the
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chaperones, leading to an accumulation of unfolded proteins, causing ER stress (Sano et
al. , 2013). The ER responds to this by activating the unfolded protein response (UPR),
which activates sensor proteins which recognize and ameliorate ER stress (Xu et al. ,
2005; Sano et al. , 2013; Zhang et al. , 2014). However, persisting ER stress leads to the
overactivation of the UPR, a highly redox dependent pathway, which is followed by an
accumulation of reactive oxygen species (ROS) (Kim et al. , 2009). ROS are a natural
byproduct of signaling pathways, however during stress, ROS production is increased
significantly, which causes oxidative stress and damage to the cell (Kim et al. , 2009).
A major source of ROS production at the ER is from the microsomal
monooxygenase (MMO) system which is composed of cytochrome P450 (CYP),
NADPH-P450 reductase (NPR) and some phospholipids (Kim et al. , 2009; Henke et al. ,
2011; Robinson et al. , 2011). Specifically, cytochrome P4502E1, a member of
cytochrome P450, is associated with the production of large amounts of ROS. This has
been shown to occur during leakage of electron transfer between P4502E1 and NPR,
thus, indicating an important role of these cytochromes during ER stress (Kim et al. ,
2009; Robinson et al. , 2011).
BI-1 has been shown to regulate ER stress induced ROS production via two
important mechanisms (Li et al. , 2014). Firstly, BI-1 can directly inhibit ROS production
by disrupting the NPR-CYP complex, which is a major contributor to ROS generation.
BI-1 causes dissociation of the complex by altering the electron flow from P4502E1 to
NPR, causing destabilization of this complex, blocking electron transfer and attenuating
ROS accumulation (Lee et al. , 2007; Kim et al. , 2009; Henke et al. , 2011). The
P4502E1 member was found to be significantly reduced and its upregulation attenuated
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after ER stress in BI-1 overexpressing cells (Kim et al. , 2009). Secondly, BI-1 can
directly increase the production of anti-oxidant factors such as nuclear factor erythroid 2related factor 2 (Nrf-2), a transcription factor the regulates ROS production (Lee et al. ,
2007; Li et al. , 2014). It does so by stimulating the production of the anti-oxidant
enzyme, heme oxygenase-1 (HO-1), which in turn blocks ROS, thereby attenuating
inflammation and promoting cell survival. G. H. Lee showed that cells overexpressing
BI-1 increased Nrf-2 activation and HO-1 expression thus blocking ROS. BI-1’s
protective effects against ER stress induced cell death were abrogated after inhibition of
HO-1 (Lee et al. , 2007).
The specific objective of this study was to establish that overexpression of BI-1
protein, with Adenoviral-TMBIM6 vector, can attenuate the morphological and
neurological consequences post neonatal HI via attenuation of ER stress induced ROS
production and inflammation. We hypothesized that BI-1 will reduce ER stress induced
ROS accumulation and subsequent inflammation via coupling with NPR and hence
disrupting the NPR-CYP complex. In addition, BI-1 can upregulate Nrf-2 which leads to
an increase in HO-1 production. HO-1 is a rate-limiting enzyme shown to be able to
attenuate ROS accumulation. Increased levels of HO-1 may limit oxidative dysregulation
which causes misfolding of ER proteins thereby decreasing the unfolded protein response
(UPR).
With this study we hope to establish a novel role for BI-1 protein in regulating ER
stress induced ROS production after neonatal HI.
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Materials and Methods
In vivo Experiments
All protocols are approved by The Institutional Animal Care and Use Committee of
Loma Linda University and with NIH guide for The Care and Use of Laboratory
Animals. The animals were cared for and all studies conducted in accordance with the
United States Public Health Service's Policy on Humane Care and Use of Laboratory
Animals. Sprague Dawley rat mothers, with litters of 10~12 pups, were purchased from
Harlan Labs (Livermore, CA). The pups were kept in temperature-controlled
environment with regular light/dark cycle until they were ready for surgery at 10days old
post birth (P10), to allow them enough time to adjust.
A total of 100 unsexed rat pups weighing 15-20g were assigned to the following
groups: sham, HI+Vehicle, HI+Ad-TMBIM6, HI+Ad-TMBIM6+BI-1siRNA, HI+AdTMBIM6+Nrf-2siRNA, HI+Ad-TMBIM6+scramble siRNA, HI+BI-1siRNA, HI+Nrf2siRNA and HI+scramble siRNA.

Hypoxic Ischemic Rat Model
Hypoxic Ischemic (HI) injury was induced as previously described following the
well-established Rice Vannucci model (Vannucci et al. , 1997; Vannucci et al. , 2004).
Briefly, P10 unsexed rats were anesthetized with 3% isoflurane gas in air and maintained
at 2.5% isoflurane during surgery. Once the rat was fully anesthetized and unresponsive,
the rats neck was prepared and draped using standard sterile techniques. A small midline
neck incision on the anterior neck was made with a No. 11 blade surgical knife
(approximately 3-5 mm in length). The right carotid artery was dissected and isolated
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from surrounding structures. The carotid artery was then double ligated with 5-O
surgical suture and cut between the ligations. Animal’s skin was sutured back to close
the incision. Throughout the surgical and postoperative period, temperature was
controlled with heating blankets and incubators. Rats were then allowed to recover for
1h on a heated blanket, then placed in a 2L Erlenmeyer airtight flask, which was partially
submerged in a 37 °C water bath to maintain a constant thermal environment. Rat pups
were exposed to a gas mixture of 8% Oxygen and 92% Nitrogen for 90min. Thereafter,
the animals were returned to their mothers and monitored daily.

Time Course Evaluation of Proteins
Time course expression of endogenous BI-1, P4502E1, NPR, pNrf-2 and HO-1
levels were measured at 6h, 12h, 24h and 72h post HI. Rats were randomly divided into
the groups and brains were collected for western blotting. Sham animals underwent
surgery; however, the artery was only isolated without being ligated or cut, and pups were
euthanized at 24h post HI.

Viral Administration
Human adenoviral-TMBIM6 vector (Ad-TMBIM6) (Vector Biolabs) was injected
intracerebroventricularly (icv) at 2µl containing 1.6x1011 PFU/ml per injection (BaillyMaitre et al. , 2010) at 48h pre-HI. The best dose and time of injection of virus was
determined in our preliminary experiments (data not shown).
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RNAi Administration
Rats were anesthetized and placed on a stereotactic frame. 2µl of BI-1 siRNA
(300pmol/µl, Sigma-Aldrich), Nrf-2 siRNA or scramble siRNA (300pmol/µl, Santa Cruz)
were administered icv using a Hamilton syringe (10µl, Hamilton Co) into the right lateral
ventricle (1.5mm posterior, 1.5mm lateral to bregma and 1.7mm down from surface of
brain) at 48h pre-HI at a rate of 0.3µl/min (Shi et al. , 2017). To prevent backflow, needle
was left in place for 10min after administration was completed and was then withdrawn
slowly over 5min. The hole was sealed with bone wax and the skin was sutured.

Infarct Area Measurements
TTC (2,3,5-Triphenyltetrazolium Chloride Monohydrate) staining was performed
at 72h post HI to determine percentage of infarcted area. Animals were anesthetized, the
brains were removed and sectioned into 2mm slices. A total of 5-6 slices were cut per
brain and were then immersed in 2% TTC solution until brains turned pink-red (~5min)
at room temperature (Zhou et al. , 2009; Li et al. , 2012). Slices were then washed in PBS
and fixed overnight in 10% formaldehyde solution and imaged. Red stained tissue
indicated live tissue while white indicated the infarcted tissue. Image J software was used
to calculate the percentage of infarcted area.
The area of each slice was calculated using the formula: ((Area of Contralateral
Hemisphere – Area of non-infarcted ipsilateral hemisphere) / 2* (Area of Contralateral
Hemisphere)) * 100 (Chen et al. , 2018; Xu et al. , 2018). The average of all 5 slices was
taken as a representative of percentage of infarcted area for each animal. All experiments
were performed in an unbiased blinded fashion.
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Western Blotting for Brain Tissue
Western blotting was performed as previously described (Li et al. , 2015; Shi et
al. , 2017; Xie et al. , 2017). Rats were anesthetized at 72h post HI and transcardially
perfused with 100ml ice cold PBS (pH 7.4). The brain was isolated and divided into
contralateral and ipsilateral hemispheres, then immediately snap frozen in liquid nitrogen
and stored in -80°C for further use. To prepare samples for western blotting, the
ipsilateral hemispheres were homogenized in RIPA lysis buffer (Santa Cruz
Biotechnology) for 15min followed by centrifugation at 14,000g at 4°C for 30min. The
supernatant was collected, and protein concentration was measured using a detergent
compatibility assay (Catalog number: 5000112, DC™ Protein Assay Kit II, Bio-Rad,
USA).
Equal amounts of protein (30μg, chosen as best loading amount based on previous
studies (Thacker et al. , 2016; Moritz 2017; Shi et al. , 2017) were loaded on an 8%~12%
SDS-PAGE gel and electrophoresed and then transferred to a nitrocellulose membrane
(0.2μm). The membrane was blocked for 1h and then incubated with primary antibodies
overnight at 4°C: BI-1 antibody (1:1000, Abcam), anti-P4502E1 (1:2500, Abcam), AntiNPR antibody (1:1000, Abcam), anti-pNrf-2/Nrf-2 antibody (1:1000, Abcam), anti-HO1
antibody (1:200, Santa Cruz Biotechnology), anti-ROMO1 antibody (1:1000, Abcam),
anti-TNFα antibody (1:1000, Abcam), anti-IL-6 antibody (1:500, Abcam), anti-Il-1β
antibody (1:500, Abcam), Anti-HA tag antibody (1:4000, Abcam) and actin (1:4000,
Santa Cruz Biotechnology). The following day, membranes were incubated at room
temperature for 1h with horseradish peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology) followed by chemiluminescence detection (ECL plus kit,
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Amersham Bioscience). The densitometric quantification of the bands was performed
with image J software and results were expressed as relative density to actin.

Histology
Brains were post-fixed in formalin, and then sectioned into 10μm thick coronal
slices by cryostat (CM3050S; Leica Microsystems) for immunohistochemistry and
Dihydroethidium (DHE) staining.
Immunofluorescence staining: Rats were anesthetized at 72h post HI and
transcardially perfused with PBS and 10% formalin. Brain sections were then post fixated
with formalin overnight and dehydrated in 30% sucrose solution for 3-5d after which
brains were frozen in OCT. Immunofluorescence staining was performed as previously
described (Shi et al. , 2017). The tissue mounted on the slides was washed with 0.1M
PBS three times for 5min and then incubated in 0.3% Triton X-100 in 0.1M PBS for
30min at room temperature. The tissue was then washed once more by 0.1M PBS for
5min, 3 times, and primary antibodies were applied overnight at 4°C: anti-BI-1 antibody
(1:100, Abcam), anti-P4502E1 antibody (1:100, Abcam), anti-NPR (1:100, Abcam), antiNrf-2 (1:100, Abcam), anti-HA tag (1:50, Abcam), anti-Iba-1 (1:100, Abcam), anti-Il-1β
(1:100, Abcam) and anti-MPO (1:100, Abcam). After washing with PBS, sections were
incubated with appropriate secondary antibodies: anti-rabbit IgG-TR, anti-mouse IgGFITC, anti-goat IgG-FITC, anti-rabbit IgG-FITC (1:200) for 2h @ RT. Finally, slides
were mounted using Vectashield Antifade with DAPI (Catalog Number: H-1200, Vector
Laboratories Inc., USA) and visualized under Fluorescent microscope (Leica DMi8,
Leica Microsystems) and Magna Fire SP system (Olympus) was used to analyze
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microphotographs. Quantification of Il-1β and MPO positive cells was manually counted
in the peri-ischemic regions. A total of 6 sections/brain were averaged and expressed as
the ratio of positive cells to total cells (%).
DHE staining: To evaluate ROS production we stained brain slices with
Dihydroethidium (DHE) stain (Owusu-Ansah et al. , 2008). Slides were prepared as
described above in Immunofluorescence staining methods. To prepare a stock solution, a
total of 25g of Dihydroethidium (DHE) (Invitrogen) solid was diluted with 1ml methanol.
The working reagent was prepared by taking 25.3µl of stock solution and diluting it in
1ml methanol. After washing slides in PBS 1x10min, a working reagent of DHE was
applied to each brain section and slides were let stand in a dark room for 30min. Slides
were then washed in PBS 3x10min, dried off, then mounted using DAPI and coverslip. A
Leica DMi8 fluorescent microscope was used to visualize the slides.

In Vitro Experiments
Rat microglial immortalized cell line, HAPI (Millipore Sigma), was used at passage 6
through 9. Cells were grown as previously described (Dickson et al. , 1986).

Oxygen Glucose Deprivation Model
Cells were grown in full growth media which was replaced with glucose deprived
media prior to being placed in a chamber. Cells were placed in a hypoxic chamber and
flushed with 1% Oxygen for 3h. Exposure of cells to 3h of OGD was chosen to be best
time from our preliminary results (data not shown). Media was removed, and complete
growth media was re-introduced to the cells. Cells were left in an incubator to recover for
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18h, after which, they were prepared for cell death assay and western blotting (Agani et
al. , 2002; Souvenir et al. , 2014).

Cell Death Assay
To determine the percentage of viable cells, we used trypan exclusion as
previously described (Souvenir et al. , 2014). Briefly, cells were scraped from the plates,
centrifuged for 5min, and then re-suspended in 10ml complete growth media. Equal
volumes of cell suspension were added to Trypan blue, cells were then vortexed and let
stand for 3min. 10µl from mixture was placed on cell counter slides and slides were read
using an automated cell counter using the average of 6 counts (Souvenir et al. , 2011).

Western Blotting for Cells
Cells were collected 18h after OGD and stored for western blotting as previously
described (Dominguez et al. , 2008; Souvenir et al. , 2014). Briefly, cells were scraped,
centrifuged and then re-suspended in 1ml PBS, after which they were centrifuged one
more time at 14000rpm for 5min. The remaining supernatant was removed after
centrifugation, leaving only the pellet. RIPA lysis buffer was added with protease
inhibitor cocktail and pipetted thoroughly until the pellet was fully dissolved. This
suspension was then left on ice for 20min following which it was centrifuged for 30min.
The supernatant was harvested while pellet was discarded. Protein concentration was
measured using Bradford assay and SD-PAGE electrophoresis was performed as
previously described (Dominguez et al. , 2008). Primary antibodies: BI-1 antibody
(1:200, Abcam), anti-P4502E1 antibody (1:1000, Abcam), anti-Nrf-2 antibody (1:1000,
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Abcam), anti-TNFα antibody (1:1000, Abcam), anti-IL-6 antibody (1:500, Abcam), antiIl-1β antibody (1:500, Abcam) and actin (1-4000, Santa Cruz) were applied to the
membrane and left overnight.

Calculation of MOI
The Multiplicity of Infection (MOI) was calculated to determine the total amount
of infectious particles needed to infect one cell. MOI was calculated as follows: #cells *
desired MOI= total PFU (or Plaque Forming Units) needed; (total PFU needed) /
(PFU/ml) = total ml of virus needed to reach your desired dose. A 100MOI of AdTMBIM6 virus was chosen as the optimal amount needed to infect cells and provide
protection from our preliminary results (data not shown).

siRNA Transfection
Cells were allowed to differentiate and reach 80% confluency in poly D-lysine coated
6 well plates prior to transfection. Both BI-1 and Nrf-2 siRNAs were prepared according
to manufacturer’s protocol (Sigma-Aldrich); A stock solution of 10µM siRNA was
prepared. From the siRNA stock,4µl was taken and mixed with 125µl Opti-MEM. In a
separate tube, 7µl liofectamine3000 was mixed with 125µl Opti-MEM. The solution from
both tubes was combined, mixed well, and left to sit at room temperature for 15-45min.
Growth media was removed from cells and replaced with 250µl/well siRNA transfection
solution as prepared above. An additional 1ml Opti-MEM was added to each well and
cells were then placed in an incubator for 5-7h, following which, the media was removed
and replaced with normal growth media.
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Statistical Analysis
Statistical analysis was performed using one-way analysis of variances (ANOVA),
followed by Tukey test. All values were presented as mean ± standard deviation (SD),
with a P-value less than 5% considered significant. Sample sizes were determined by
power of 0.8, α=0.05, and a 20% standard deviation from the preliminary results. The
estimated sample size was 6-8/group for in vivo studies and 4/group for cell culture
studies. All rats were randomly assigned to each group and all investigators were blinded.

Results
Time Course Expression of Endogenous Proteins post HI
Endogenous expression of BI-1, NPR, P4502E1, pNrf-2 and HO-1 were measured at
6h, 12h, 24h and 72h post HI. BI-1 levels significantly increased at 24h post HI and
returned to sham levels at 72h post HI (Figure 3.1A-B). While NPR expression levels
showed no changes (Figure 3.1B), P4502E1 significantly increased in a time dependent
manner, reaching peak at 72h post HI (Figure 3.1C). Nrf-2 levels significantly decreased
from 6h to 72h, reaching significantly lower expression levels at 72h post HI compared to
sham (Figure 3.1D). Lastly, HO-1 showed to peak at 24h post HI (Figure 3.1E).
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Figure 3.1 Endogenous Expression levels of BI-1, NPR, P4502E1, Nrf-2 and HO-1
post HI
Representative pictures of Western blot bands (A). BI-1 expression levels significantly
increased in a time-dependent manner from 6h to 24h and returned to sham levels at 72h
post HI (B). There were no changes in endogenous NPR levels among the groups (C). The
expression of P4502E1 increased at 6h and remained elevated, reaching significance at
72h post HI (D). Nrf-2 levels decreased in a time-dependent manner (E). HO-1 levels
increased at 24h and 72h post HI (Data expressed as mean +/- SD; *p<0.05 vs sham; # p
＜0.05 vs 6h, @ p < 0.05 vs 24h; n=4, using one-way ANOVA followed by Tukey multiplecomparison post hoc analysis).
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To Determine Amount of Ad-TMBIM6 Viral Vector Present in the Brain and
its Effects on Infarction at 72h post HI
To determine amount of Ad-TMBIM6 present in the brain at 72h post HI, western
blot was performed using anti-HA tag antibody. This specifically measures how much
virus was in the brain when administered 48h pre-HI. Quantification data showed that
there was significant amount of Ad-TMBIM6 present at 72h post HI versus nothing in
sham or vehicle. To further confirm these findings, IHC staining results indicated a large
expression of Ad-TMBIM6 in the brain when stained with anti-HA tagged antibody
(Figure 3.2A). There was no staining seen for Ad-TMBIM6 in sham or vehicle (data not
shown).
To evaluate the effects of pathway interventions on the percentage of infarcted area,
we used a BI-1 inhibitor (BI-1 siRNA) and a Nrf-2 inhibitor (Nrf-2 siRNA). Results
showed that Ad-TMBIM6+BI-1siRNA significantly reversed BI-1’s protective effects as
did Ad-TMBIM6+Nrf-2siRNA group. This is seen from the significant increase in
percent infarcted area when compared to Ad-TMBIM6 only group (Figure 3.2B). Control
group, Ad-TMBIM6+scramble siRNA, did not exacerbate the damage when compared to
Ad-TMBIM6 treated group. Furthermore, BI-1 and Nrf-2 siRNA only groups (without
treatment) showed similar percent infarcted area as compared to HI+vehicle or
HI+scramble siRNA groups.
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Figure 3.2 Inhibition of BI-1 or Nrf-2 increased percent infarcted area at 72h Post HI
Anti-HA tagged antibody was used to measure amount of viral vector present in the brain
at 72h post HI. Western blot data indicated a significant expression of Ad-TMBIM6 in the
brain after intracerebroventricular administration (A) Percent infarct area was significantly
increased in vehicle, BI-1siRNA and Nrf-2 siRNA groups when compared to Ad-TMBIM6
and the respective control group (B). (Data expressed as mean +/− SD; *p<0.05 vs sham;
#p<0.05 vs vehicle; @p<0.05 vs Ad-TMBIM6 or scramble; n=6-8/group using one-way
ANOVA followed by Tukey multiple-comparison post hoc analysis).
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Overexpression of BI-1 Disrupted the NPR-CYP Complex at 72h post HI
To determine BI-1’s role on the NPR-CYP complex the following groups were used:
sham, vehicle, Ad-TMBIM6, Ad-TMBIM6+BI-1siRNA, Ad-TMBIM6+Nrf-2 siRNA,
Ad-TMBIM6+scramble siRNA, HI+BI-1siRNA only, HI+Nrf-2siRNA only and
HI+scramble siRNA only groups.
Quantification data showed that BI-1 expression levels were significantly increased in
the Ad-TMBIM6 treatment and in the Ad-TMBIM6+scramble siRNA groups, while BI-1
siRNA reversed those effects (Figure 3.3A-B). In addition, all three groups (without AdTMBIM6) BI-1 siRNA, Nrf-2 siRNA and scramble, showed low expression levels of BI1 versus Ad-TMBIM6.
Ad-TMBIM6 significantly reduced expression of P4502E1 (Figure 3.3C), while
silencing BI-1 reversed those effects, as seen from the elevated expression levels of
P4502E1 (Figure 3.3C).
To observe changes in BI-1 and P4502E1 expression levels, as well as co-localization
with microglia, after either Ad-TMBIM6 or after silencing of BI-1 and Nrf-2,
immunofluorescence staining was performed. Data showed increased expression of BI-1
and colocalization on microglia in Ad-TMBIM6 treatment group and scramble control
group compared to sham or vehicle while BI-1 siRNA reversed those effects (Figure
3.3D). On the contrary, P4502E1 expression levels were elevated in vehicle, BI-1 siRNA
and Nrf-2 siRNA groups but not in sham or Ad-TMBIM6 treated groups (Figure 3.3E).
There was also col-localization of P4502E1 on microglia.

112

Figure 3.3 The effects of BI-1 inhibition on the NPR-CYP complex at 72h post HI
Representative picture of western blot data (A). Quantification of bands showed that AdTMBIM6 as well as control group (Ad-TMBIM6+scramble siRNA) significantly increased
BI-1 expression levels in the brain when compared to vehicle or sham, while, BI-1 siRNA
and Nrf-2 siRNA significantly reversed those effects. Furthermore, BI-1 and Nrf-2 siRNA
only groups also reduced BI-1’s expression levels (B). Data showed that P4502E1
expression levels were significantly elevated in vehicle and BI-1 siRNA groups whereas
Ad-TMBIM6 and control group reversed those effects (C) at 72h post HI. (Data expressed
as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05 vs Ad-TMBIM6 or
scramble; n=6/group using one-way ANOVA followed by Tukey multiple-comparison post
hoc analysis).
Immunofluorescence staining showed a significantly higher expression of BI-1 on
microglia in Ad-TMBIM6 treatment and scramble groups compared to sham or vehicle,
while BI-1 siRNA reversed those effects (D). Staining showed higher expression and colocalization of P4502E1 on microglia in vehicle, BI-1 siRNA and Nrf-2 siRNA groups
compared to sham or Ad-TMBIM6 treated groups (E). (Green was for microglial staining,
Red was for BI-1/ or P4502E1 staining and Blue was for DAPI). Merge showed the
colocalization of BI-1 or P4502E1 on microglia (D-E). (Scale bar = 50 μm; n=3/group).
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BI-1 Upregulated pNrf-2 Expression and Induced Anti-Oxidant Enzyme
Production at 72h post HI
To evaluate overexpression of BI-1 on Nrf-2 levels and its ability to upregulate antioxidant enzymes needed to block ROS, the following groups were employed: sham,
vehicle, Ad-TMBIM6, Ad-TMBIM6+BI-1siRNA, Ad-TMBIM6+Nrf-2 siRNA, AdTMBIM6+scramble siRNA, HI+BI-1siRNA only, HI+Nrf-2siRNA only and HI+scramble
siRNA only groups. Quantification data of western blot bands indicated a significantly
higher expression of pNrf-2 in Ad-TMBIM6 treated groups when compared to vehicle.
Either silencing BI-1 or Nrf-2 with siRNAs reversed those effects (Figure 3.4A, C). An
increase in Nrf-2 levels was followed by an increase in the anti-oxidant enzyme HO-1 in
the Ad-TMBIM6 group when compared to vehicle (Figure 3.4A, D). Furthermore,
inhibition of BI-1 or Nrf-2 significantly decreased HO-1 levels and its ability to block
ROS.
In addition, to look at expressions of NPR and Nrf-2 and co-localization with
microglia in the presence of Ad-TMBIM6 as well as with BI-1 and Nrf-2 inhibition, we
performed immunohistochemical staining. Fluorescent staining showed that although
NPR co-localized with microglia, its expression levels were unchanged among groups
(Figure 3.4E). On the contrary, Ad-TMBIM6 increased Nrf-2 expression and colocalization with microglia compared to sham or vehicle, while Nrf-2 siRNA abolished
that effect (Figure 3.4F).
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Figure 3.4 BI-1’s role in the Nrf-2 signaling pathway at 72h post HI
Representative picture of western blot data (A). No changes were observed in NPR
expression levels among groups (B) Quantification of bands showed that Ad-TMBIM6 as
well as control group (Ad-TMBIM6+scramble siRNA) significantly upregulated pNrf-2
levels versus vehicle, BI-1 siRNA and Nrf-2 siRNA groups (C) Ad-TMBIM6 significantly
upregulated HO-1 expression levels while BI-1 siRNA and Nrf-2 siRNA reversed those
effects (D). (Data expressed as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle;
@p<0.05 vs Ad-TMBIM6 or scramble; n=6/group using one-way ANOVA followed by
Tukey multiple-comparison post hoc analysis).
Immunofluorescence staining showed minimal changes in NPR expression among groups
(E) while Nrf-2 levels were upregulated in Ad-TMBIM6. Those effects were abolished in
the Nrf-2 siRNA group (F). (Green was for microglial staining, Red was for NPR / or Nrf2 staining and Blue was for DAPI. Merge showed the colocalization of NPR or Nrf-2 on
microglia (E-F). (Scale bar = 50μm; n=3/group).
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BI-1 Overexpression Attenuated ROS Production and Inflammation at
72h Post HI
To evaluate whether over expression of BI-1 with Ad-TMBIM6 could inhibit
ROS production and subsequently attenuate inflammation, western blot was done to
quantify ROMO1 (a modulator that induces production of ROS), IL-6, TNFα and IL-1β
expression levels. Data showed that Ad-TMBIM6 treatment group significantly reduced
ROMO1 levels (Figure 3.5A-B) and attenuated pro-inflammatory markers, IL-6, TNFα
and IL-1β (Figure 3.5C-E). In addition, administration of BI-1 siRNA and Nrf-2 siRNA
reversed Ad-TMBIM6’s protective effects as seen from the significantly higher
upregulation of pro-inflammatory mediators and ROS.
Since HI results in induction of inflammation, we stained for IL-1β (a proapoptotic marker) with microglia. The counting of positively stained cells for IL-1β with
microglia showed a higher percentage of IL-1β on microglia in vehicle, BI-1 siRNA and
Nrf-2 siRNA groups compared to sham, Ad-TMBIM6 or scramble group. (Figure 3.5F;
Scale bar 50µm).
To evaluate ROS production, we stained brain slices with Dihydroethidium
(DHE) dye. Cells with high ROS accumulation will have a red fluorescent light. Our data
revealed a higher number of red positively stained cells in vehicle and siRNA groups
versus sham, Ad-TMBIM6 and control group in cortex region (Figure 3.6A).
Furthermore, we also stained for ROS around the ventricles and observed trends
similar to the cortex region (Figure 3.6B). In addition, to determine whether ROS
accumulation is correlated with increased inflammation we stained for Myeloperoxidase
(MPO; a marker that shows the inflammatory activity) and detected significantly higher
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expression of MPO positively stained cells in vehicle and siRNA groups compared to
sham or Ad-TMBIM6 treated group (Figure 3.6C).Thus showing both a correlation
between an increase in ROS production with an increase in inflammation, as well as BI1’s ability to inhibit ROS production and the increase in inflammation independently.
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Figure 3.5 Overexpression of BI-1 attenuated ROS production and inflammation at
72h post HI
Representative picture of western blot data showing bands of the expression levels
of ROMO1, IL-6, TNFα and IL-1β (A). Western blot data quantification of bands showed
that Ad-TMBIM6 significantly reduced ROMO1 (B), IL-6 (C), TNFα (D) and IL-1β (E)
expression levels compared to vehicle, sham, BI-1 siRNA or Nrf-2 siRNA groups. (Data
expressed as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05 vs AdTMBIM6 or scramble; n=6/group using one-way ANOVA followed by Tukey multiplecomparison post hoc analysis).
Fluorescent staining detected significantly more positively IL-1β stained microglia in
vehicle, BI-1 siRNA and Nrf-2 siRNA groups compared to sham or Ad-TMBIM6 treated
groups (F). (Green was for microglial staining, Red was for IL-1β. Merge showed the
colocalization of IL-1β on microglia (E-F). Scale bar 50µm; n=3/group).
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Figure 3.6 Fluorescent staining demonstrated BI-1’s ability to reduce ROS production
and attenuate inflammation at 72h post HI
DHE staining for ROS demonstrated that Ad-TMBIM6 reduced the amount of positively
stained cells when compared to vehicle, BI-1 siRNA or Nrf-2 siRNA groups in the cortex
(A). DHE staining around ventricles showed more positively stained ROS cells in vehicle
compared to sham or Ad-TMBIM6 group (B). MPO staining for inflammation showed a
significant reduction in positively stained MPO cells in Ad-TMBIM6 and sham groups
compared to vehicle and siRNA groups (C). (Red was for ROS or MPO staining and Blue
was for DAPI. Merge shows the number of positively stained cells (E-F). (For panel A
scale bar = 50μm; For panel B scale bar = 100μm; For panel C scale bar = 25 μm;
n=3/group).
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To Investigate BI-1’s Effects on NPR-CYP Complex in an in vitro OGD Model
As BI-1 has been previously reported to disrupt the NPR-CYP complex as well as
activate Nrf-2 resulting in inhibition of ROS production and subsequent attenuation of
inflammation, we employed an in vitro OGD model using a microglial cell line to test the
specificity of BI-1 related attenuation of ROS induced inflammation in microglia. To test
BI-1’s pathway, we administered a BI-1 siRNA to knockdown BI-1 expression levels and
a Nrf-2 siRNA to silence Nrf-2 expression. Data showed that administration of AdTMBIM6 vector significantly upregulated BI-1 levels in cells, both in treated and
scramble control group, while BI-1 siRNA group reversed those effects, Nrf-2 siRNA did
not affect BI-1’s levels (Figure 3.7A-B). Intervening at either BI-1 level or Nrf-2 level
with siRNAs significantly reversed BI-1’s protective effects as seen from the increased
expression levels of inflammatory markers, IL-6, TNFα and IL-1β when compared to AdTMBIM6 treated group, sham or scramble groups (Figure 3.7C-E). Ad-TMBIM6
inhibited P4502E1, the major source of ROS production, while simultaneously
upregulating pNrf-2 levels (Figure 3.7F-G). Silencing BI-1 or Nrf-2 reversed those
effects. Percent cell viability data showed that Ad-TMBIM6 was able to significantly
improve the percent of viable cells while knockdown of BI-1 and Nrf-2 reversed those
effects (Figure 3.7H).
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Figure 3.7 BI-1 exerted its anti-inflammatory effects via inhibition of P4502E1 and
upregulation of Nrf-2 in an in vitro OGD model
Representative picture of western blot bands showing protein expression levels (A).
Quantification data of bands showed that BI-1 expression levels were significantly
increased in the Ad-TMBIM6 treatment group and in scramble control group, while BI-1
siRNA reversed that effect (B). Ad-TMBIM6 and scramble control group significantly
reduced IL-6 (C), TNFα (D) and IL-1β (E) expression levels. Expression levels of P4502E1
were significantly upregulated in vehicle, BI-1 siRNA and Nrf-2 siRNA groups versus
sham, Ad-TMBIM6 treated group or scramble control group (F). Ad-TMBIM6 and
scramble control group significantly upregulated pNrf-2 levels which was reversed by BI1 siRNA and Nrf-2 siRNA (G). Cell viability data showed a significantly higher percentage
of viable cells in Ad-TMBIM6 group and scramble control group versus vehicle, BI-1
siRNA or Nrf-2 siRNA groups (H). (Data represent +/− SD; *p<0.05 vs control; #p<0.05
vs vehicle; @p<0.05 vs Ad-TMBIM6 and scramble; $p<0.05 vs BI-1 siRNA; n=4-5/group
using one-way ANOVA followed by Tukey multiple-comparison post hoc analysis).
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Discussion
The Endoplasmic Reticulum (ER) is a major organelle that has an essential role in
multiple cellular processes. One of these major roles is the control of correct protein
folding and function (Xu et al. , 2005; Zhang et al. , 2014). A wide variety of external
factors may contribute to a disruption in ER homeostasis, such as hypoxia ischemia,
oxidative stress, calcium disturbances and inhibition of protein glycosylation, which all
cause ER stress (Zhang et al. , 2014). Cells may respond to ER stress in various ways,
activating several pathways, including promoting the ability of proteins to refold
correctly, inhibiting protein translation, increasing protein degradation, stimulating the
transcription of genes and enabling self-repair mechanisms (Zhang et al. , 2014). All
these processes are referred to as the unfolded protein response (UPR) which under
prolonged activation result in cell death (Xu et al. , 2005).
Bax Inhibitor-1 (BI-1) is an evolutionary conserved protein that resides on the
intracellular membranes of the ER (Henke et al. , 2011). BI-1 was first named as Bax
Inhibitor due to its ability to suppress cell death in yeast (Xu et al. , 1998). More recently
it is also referred to as TMBIM6 as it is part of the transmembrane Bax Inhibitor-1
containing motif 6 family (Li et al. , 2014). Overexpression of BI-1 has been
demonstrated to play protective role in ER stress-induced cell death, and to a lesser extent
in other ER related stresses, such as oxidative stress and inflammation.
ER stress is associated with the production of reactive oxygen species (ROS)
through oxidative protein folding by the NADPH-P450 reductase (NPR), as well as the
microsomal monooxygenase system, which is composed of cytochrome P450 (CYP)
members such as P4502E1 (Nieto et al. , 2002; Nieto et al. , 2002; Robinson et al. ,
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2011), which triggers the UPR. Study have shown that BI-1 overexpressing cells can
regulate UPR induction and inhibit ROS accumulation under ER stress (Kim et al. ,
2009), thus making BI-1 a possibly key regulator of ROS inhibition. Cells respond to
ROS by activating genes to encode antioxidative stress enzymes. A key transcription
factor activated is nuclear factor erythroid 2-related factor 2 (Nrf-2), which regulates the
production of several cytoprotective enzymes, such as heme oxygenase-1 (HO-1). HO-1
is a rate limiting enzyme and a potent inhibitor of ROS production (Lee et al. , 2007; Kim
et al. , 2009). Studies show, that in BI-1 overexpressing cells, the inhibition of HO-1
attenuated BI-1 mediated protection against ER stress (Lee et al. , 2007). However, the
role of HO-1 in BI-1’s protective mechanism is largely unknow and debatable.
Some studies have shown that HO-1 was unaffected in BI-1 deficient mice
embryonic fibroblast cells (Lisbona et al. , 2009). In contrast, BI-1 overexpressed cells
showed significant suppression of ROS production in human embryonic kidney cells
(Kim et al. , 2012). Moreover, this was shown to be due to BI-1’s inhibitory effects on
P4502E1 expression(Kim et al. , 2009). The P4502E1 member of the cytochrome P450
ER heme proteins, is a major contributor to ROS production. It acts by metabolizing and
activating substrates into more toxic products, thus not only increasing ROS production
but also stimulating inflammatory cascades and ultimately worsening HI pathology.
P4502E1 has been shown to be upregulated during ER stress in several studies (Lee et
al. , 2007; Kim et al. , 2009; Kim et al. , 2012; Lee et al. , 2012), thus playing an
important role in HI pathology.
BI-1 may inhibit ROS accumulation by binding to NPR and disrupting the NPRCYP complex by decreasing electron uncoupling. It was found that BI-1 overexpressing
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cells caused P4502E1 degradation, leading to ER stress suppression, and subsequently
causing ROS reduction (Lee et al. , 2012). In addition, other studies showed that
P4502E1 induced oxidative stress played a role in translocation of Nrf-2 to the nucleus
followed by upregulation of anti-oxidant gene HO-1. Moreover, increased HO-1 levels
may be dependent on P4502E1 (Gong et al. , 2003), perhaps attempting to counteract
P4502E1 effects and act as survival signal. The same study showed that inhibition of
P4502E1 significantly reduced ROS generation in an acute kidney injury model (Wang et
al. , 2014). The relationship between P4502E1 and HO-1 needs further research to fully
understand the specifics covering the apparent connection. Since P4502E1 is a major
regulator of ROS production and that Nrf-2 has a role in the response against P4502E1,
inhibition of P4502E1 coupled with activation of Nrf-2 is a promising therapeutic target.
Therefore, in this study we investigated the role of overexpressing BI-1, by administering
Adenoviral-TMBIM6 vector intracerebroventricularly at 48h pre-HI, on ER stress
induced accumulation of ROS and subsequent inflammation. We hypothesized that BI-1
may carry this protective effect by interacting with the CYP-NPR complex while also
upregulating Nrf-2 levels.
Although we are now beginning to understand the importance of BI-1 in the cell
and in human physiology, its function and signaling mechanisms remain unknown. In
view of the importance of P4502E1 and Nrf-2, finding a key molecule to regulate both is
of great interest. Here we identified BI-1 as one such potential molecule which may
protect the cell against ER stress induced ROS production as well as the subsequent
increase in inflammatory response via two possible mechanisms. First, it may interact
with NPR, thus destabilizing the NPR-CYP complex, which directly inhibits the
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formation of ROS by reducing the activity of P4502E1 (Kim et al. , 2009). BI-1 may
interact though its C-terminus with NPR and to lesser extend with P4502E1 (Kim et al. ,
2009). This interaction induces destabilization of the NPR-CYP complex, thus blocking
electron transfer and ROS production (Robinson et al. , 2011). A recent study showed that
BI-1 was able to inhibit ER stress induced ROS production via a reduction in P4502E1
activity and protein expression (Kim et al. , 2009). We observed similar findings from our
western blot results; overexpression of BI-1 in the neonatal rat significantly upregulated
BI-1 levels in the brain, while simultaneously reduced P4502E1 expression levels (Figure
3.3A-C). Inhibition of BI-1 with BI-1 siRNA reversed those effects, while inhibition of
Nrf-2 did not seem to significantly change P4502E1 levels, indicating its action as
downstream. This data was further supported by our IHC staining that demonstrated
across groups that: as BI-1 expression increased, P4502E1 decreased; they have converse
expression patterns throughout (Figure 3.3D-E).
Secondly, BI-1 may upregulate Nrf-2 which in turn triggers HO-1 thus inhibiting
ROS production and attenuating inflammation. Lee et al 2007 showed that
overexpression of BI-1 in cells increased Nrf-2 transcription factor, which then
translocated to the nucleus where it stimulated production of anti-oxidant enzymes such
as HO-1. HO-1 is known to block ROS production and accumulation thereby promoting
cell survival (Lee et al. , 2007). Similar to Lee et al, we found that BI-1 overexpression,
after neonatal HI, significantly upregulated Nrf-2 (Figure 3.4C) and HO-1 (Figure 3.4D)
while silencing of either BI-1 or Nrf-2 with siRNAs reversed those effects. In addition,
our IHC staining showed changes in Nrf-2 expression patters among groups which
correlated with our western blot findings (Figure 3.4F). Furthermore, inhibition of
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P4502E1 with activation of Nrf-2 and HO-1 was linked with reduction in ROS
accumulation and the subsequent release of pro-inflammatory mediators. Here, we used a
ROS marker, Reactive Oxygen Species Modulator 1 (ROMO1), which is protein coding
gene responsible for ROS generation. There was a significant reduction in ROMO1
expression levels (Figure 3.5A-B) as well as in IL-6, TNF-α and IL-β (Figure 3.5C-D).
Staining for IL-1β on microglia demonstrated a significantly higher expression and
colocalization in vehicle, BI-1 siRNA and Nrf-2 siRNA groups compared to sham or AdTMBIM6 treated group (Figure 3.5F). These results were confirmed to be via BI-1
induced inhibition of P4502E1 or activation of Nrf-2 as either inhibition of BI-1 or Nrf-2
reversed those effects. To further examine BI-1’s inhibitory role on ROS accumulation,
we used a Dihydroethidium (DHE) dye was used to detect ROS production. DHE is
possibly the most specific and least problematic dye for detection of superoxide radicals
(Owusu-Ansah et al. , 2008). Once cells are stained with DHE, the dye binds with the
superoxide anions, thus illuminating a red fluorescent image which is an indication of
ROS presence. Our data indicated a higher amount of ROS accumulation in vehicle, BI-1
siRNA and Nrf-2 siRNA groups versus sham or Ad-TMBIM6 treated groups, in both
cortex region and around ventricles, while overexpression of BI-1 showed a reduction in
ROS (Figure 3.6A-B). To detect whether a reduction in ROS was associated with a
reduction in inflammation we performed immunofluorescence staining for
Myeloperoxidase (MPO). Similar pattern was observed in the MPO staining where AdTMBIM6 significantly reduced MPO positively stained cells compared to vehicle, BI-1
siRNA or Nrf-2 siRNA groups (Figure 3.6C) thus indicating a correlation between a
reduction in ROS and the subsequent attenuation of the inflammatory processes.
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In summary, overexpression of BI-1 with Ad-TMBIM6, promotes cell survival by
increasing production of anti-oxidant enzymes as well as destabilizing the complex
responsible for ROS production. This was observed as inhibition either at the BI-1 or
Nrf-2 level; with siRNAs reversed BI-1’s protective effects by altering P4502E1, Nrf-2
and HO-1 expressions. This is indicative of BI-1’s ability to interact with the NPR-CYP
complex and induce dissociation, thus disrupting the electron flow, as a physical
association between NPR and CYP is required for production of ROS. Furthermore, BI-1
was shown to directly upregulate Nrf-2 thus triggering HO-1 to inhibit ROS. These two
mechanisms play a major role in BI-1’s anti-inflammatory effects.
To ensure the above in vivo results were also specific to microglia, we employed
an in vitro oxygen glucose deprivation (OGD) model in an immortalized microglial cell
line. HAPI cells were transfected with (1) BI-1 siRNA in combination with human
adenoviral TMBIM6 (Ad-TMBIM6; gene responsible for expressing BI-1 (Bailly-Maitre
et al. , 2010) vector to test the role of the BI-1 and NPR-CYP complex; and (2) Nrf-2
siRNA together with Ad-TMBIM6 to test the involvement of Nrf-2 and HO-1 in BI-1’s
effects. Cells were collected after OGD and used for cell viability and western blot
analysis. Cell viability data indicated that Ad-TMBIM6 significantly increased the
percentage of viable cells when compared to cells that underwent 3h OGD without AdTMBIM6 (Vehicle) (Figure 3.7). Furthermore, BI-1 siRNA or Nrf-2 siRNA significantly
reversed Ad-TMBIM6s protective effects (Figure 3.7).
Western Blot experiments further supported our cell viability data (Figure 3.7).
Results indicated that Ad-TMBIM6 successfully upregulated BI-1’s expression levels in
HAPI cells, while concomitantly reducing the pro-inflammatory markers (Figure 3.7).
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Inhibition either with BI-1 siRNA or Nrf-2 siRNA increased the pro-inflammatory
markers. In addition, similar trends were seen in our in vitro model for P4502E1 and Nrf2 levels in comparison to our in vivo model. Data showed that while BI-1 overexpressing
cells successfully reduced P4502E1 levels while upregulating Nrf-2, either inhibiting BI1 or Nrf-2 reversed that trend.
This data showed a strong support of BI-1’s ability to inhibit P4502E1 thus
disrupting the complex while upregulating the anti-oxidant factor Nrf-2, hence
attenuating ROS production and inflammation after HI. These data expand the current
evidence on BI-1 as a protective protein and advance the in vitro studies done by Kim et
al and Lee et al to a in vivo stroke model. A major challenge with any design to inhibit
either cell death pathways or inflammatory pathways caused by ER stress lies in the
existence of the several parallel pathways that may act at the same time. Thus, focusing
on only one may not be ideal to preserve cell survival. Based on the evidence, BI-1’s role
as both an anti-inflammatory mediator, and as an anti-apoptotic protein with its ability to
influence several major ER stress related pathways, makes BI-1 an ideal and promising
candidate for potential therapeutic approach.
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CHAPTER FOUR
DISCUSSION AND CONCLUSION
The role of Bax Inhibitor-1 (BI-1) as a potential therapeutic target against
Endoplasmic Reticulum (ER) stress and its potential effects on pathophysiological
outcomes after hypoxic ischemic (HI) insult has not been reported previously. Several
studies have shown BI-1’s anti-apoptotic and anti-oxidative properties (Chae et al. ,
2004; Kim et al. , 2009; Bailly-Maitre et al. , 2010), however, little is known about its
signaling mechanism which limits its clinical translation. In this study, we showed for the
first time that overexpressing BI-1, with gene delivery of adenoviral-TMBIM6 (AdTMBIM6) vector, attenuated short and long-term deficits after HI in a neonatal rat pup.
BI-1’s protection was mediated through IRE1α inhibition as well as through dissociation
of the NPR-CYP complex coupled with upregulation of Nrf-2.
We employed both an in vitro, oxygen glucose deprivation (OGD) model, and in
vivo neonatal hypoxic ischemic model in rat pup. The main findings of our study are: (1)
In vitro experiments using the OGD model showed that cells transfected with AdTMBIM6 significantly improved cell viability, whereas silencing the TMBIM6 gene
reversed those effects. (2) In our OGD experiments we elucidated at least one major
pathway via which BI-1 attenuated apoptosis. Results indicated that BI-1 exerts its antiapoptotic effects via inhibition of IRE1α and to a lesser extend via PERK. (3)
Administration of Ad-TMBIM6 in a neonatal rat subjected to HI, improved both short
and long-term outcomes after HI. (4) At Least one of BI-1’s signaling pathways was
confirmed to be via IRE1α inhibition, and its downstream molecules, thus attenuating
apoptosis, in a rat HI model. (5) BI-1 disrupted the NPR-CYP complex, which was
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coupled with upregulation of Nrf-2 and anti-oxidant enzymes, HO-1, and this attenuated
ROS generation and subsequent inflammation.
Historically, there has been a vast focus on anti-apoptotic and anti-inflammatory
processes after hypoxic or ischemic events. Specifically, the Bcl-2 protein family has
been extensively studied in this context, but reports have shown that most members of
that family are poorly conserved in animals (Rojas-Rivera et al. , 2015). In contrast, the
TMBIM family are highly conserved evolutionary proteins with common ancestors in
yeast (Xu et al. , 1998; Rojas-Rivera et al. , 2012). One member of the TMBIM family,
Bax Inhibitor-1 (BI-1) protein, has been well described as an anti-apoptotic protein
conferring protection in cells and animal studies (Bailly-Maitre et al. , 2006; Lee et al. ,
2007; Kim et al. , 2009; Lisbona et al. , 2009). The BI-1 is a small, six-helix domain
protein located primarily in the endoplasmic reticulum (ER) (Xu et al. , 1998). It was first
identified in human screening to evaluate proteins that could inhibit Bax-mediated cell
death (Xu et al. , 1998). It was first referred to as the testis enhanced gene transcript
(TEGT), as it was found to be in high abundance in rat and mouse testis (Walter et al. ,
1994; Walter et al. , 1995). The gene was also detected in the brain, liver, kidney,
thalamus, lung, ovary and heart of rat (Walter et al. , 1994).
Since its initial discovery, BI-1’s anti-apoptotic effects have been studied
extensively by many groups. BI-1protected yeast cells and HEK293 cells against
overexpression of Bax (Xu et al. , 1998). It was protective in plants by inhibiting Bax and
H2O2 (Kawai et al. , 1999). BI-1 can even attenuate Chlamydia induced apoptosis in
HeLa cells (Perfettini et al. , 2002).
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With more and more emerging studies it soon became evident that BI-1’s
protection was most prominent in ER stress and ischemia-reperfusion injury. ER stress is
a major pathology encountered due to the accumulation of misfolded proteins, after HI. A
series of in vitro studies were employed that showed BI-1’s protection against various ER
stress inducers like thapsigargin, and tunicamycin, which are both inhibitors of transport
of proteins between ER and Golgi (Chae et al. , 2004). BI-1 also showed protection in
HEK293 cells and neuronal cells after oxygen glucose deprivation (OGD) (Bailly-Maitre
et al. , 2006). Studies then moved on to culturing cells from transgenic animals
overexpressing BI-1, this demonstrated that cells were protected when exposed to various
stresses (Chae et al. , 2004). In contrast, cells that were cultured from BI-1 deficient
models were much more sensitive to ER stress or ischemia reperfusion injury (Krajewska
et al. , 2011). Similarly, knock down of BI-1 using shRNAs also demonstrated increased
sensitivity to ER stress in HeLa cells (Xu 2008). In recent studies of in vivo models of
ischemia-reperfusion, traumatic brain injury or SAH, BI-1 overexpression conferred
protection by interfering with ER stress induced apoptotic signals (Chae et al. , 2004;
Krajewska et al. , 2011; Shi et al. , 2018).
BI-1 has also been described in diverse other functions. BI-1 acted as a negative
regulator of ER stress sensors, such as IRE1α (Lisbona et al. , 2009), it can increase actin
polymerization (Lee et al. , 2010), regulate the release of calcium from intracellular
stores (Chae et al. , 2004) and reduce reactive oxygen species (ROS) generation by direct
interaction with members of the microsomal monooxygenase system (MMO),
cytochrome P450 (CYP) and NADPH-P450 reductase (NPR) (Kim et al. , 2009).
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In vitro studies described BI-1’s protective functions to be against ER stress
inducers. Bailly- Maitre and colleagues used BI-1 knockout samples, from liver and
kidney, to analyze ER stress markers (Bailly-Maitre et al. , 2006). The most striking
results were the evident increase of the spliced X-box-binding protein-1 (XBP1), which is
a downstream regulator of IRE1α. This data was later confirmed by Lisbona et al, where
a significant increase of XBP1 was observed in BI-1 knockout animals which was
correlated with an increase in IRE1α activity (Lisbona et al. , 2009). There was
speculation that BI-1 may have some direct relationship with IRE1α-XBP1, since wild
type cells that were treated with ER stress inducers, like tunicamycin, showed an initial
increase in XBP1 which then decreased over time. However, in BI-1 knockout cells, the
levels of XBP1 remained elevated, thus suggesting inhibitory function of BI-1 on XBP1.
This observation was soon confirmed to be via BI-1’s inhibitory effect on IRE1α-XBP1
by direct interaction with IRE1α protein through its C-terminus (Lisbona et al. , 2009).
Co-immunoprecipitation experiments have shown this direct interaction between BI-1
and IRE1α. In a cell culture study where cells were BI-1 deficient, knockdown of either
IRE1α or XBP1 further exacerbated the damage caused by tunicamycin (Lisbona et al. ,
2009). BI-1’s role was also reported in obesity. It regulated glucose metabolism and
reversed hyperglycemia in obese mice that were administered adenoviral-TMBIM6
vector, which caused them to overexpress BI-1 (Bailly-Maitre et al. , 2010). This was
hypothesized to be via the inhibition of IRE1α and attenuation of XBP1 splicing in mice
overexpressing BI-1 in liver. This gives a strong support to BI-1’s role on ER stress
sensors, however, more work is needed to show this intricate relationship and its effects
in stroke.

139

Some reports have shown that BI-1 may also indirectly inhibit another ER stress
induced protein, PERK (Lee et al. , 2007). In contrast, another study reported that BI-1
may not have any effect on that pathway, as eIF2α phosphorylation levels, a downstream
factor of PERK, were unchanged in BI-1 knockout mice (Bailly-Maitre et al. , 2006).
Therefore, due to the controversies of BI-1’s role in PERK signaling, we used an
OGD model to first establish BI-1’s role on the two branches of the UPR that are
activated during ER stress, IRE1α and PERK. We intervened at both receptor levels to
help us elucidate BI-1’s predominant pathway via which it attenuates ER stress induced
apoptosis. Our data indicated that cells transfected with Ad-TMBIM6 significantly
improved percent cell viability after 3h of OGD, while silencing BI-1 reversed those
effects. In conjunction with above mentioned studies, we also observed an inhibition of
IRE1α and XBP1 in cells overexpressing BI-1, while either inhibiting BI-1 or using an
IRE1α agonist (APY-29) abrogated those effects and exacerbated the injury. This was
seen from the increase in the pro-apoptotic marker, cleaved-caspase 3, levels.
Furthermore, we compared BI-1’s role on the IRE1α branch to the PERK branch and
observed that cells overexpressing BI-1, that were transfected with either a PERK
agonist, CCT020312, or inhibition of PERK with a CRISPR k/o, did not alter BI-1’s
expression levels. Additionally, cleaved caspase-3 levels were lower in BI-1
overexpressing cells transfected with an IRE1α inhibitor versus that of cells transfected
with PERK inhibitor. This is an indication that BI-1 may more potently attenuate
apoptosis via IRE1α inhibition than via PERK inhibition. This result suggests that a
direct interaction exists between BI-1 and IRE1α, but not between BI-1 and PERK, thus
BI-1 has a more potent effect on IRE1α (Lee et al. , 2007; Lisbona et al. , 2009). Our data
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also supports that interaction, as we saw intervening at IRE1α levels caused changes in
BI-1 expression patterns whereas manipulation of PERK did not alter BI-1’s levels.
To date, BI-1’s role and signaling mechanisms have not been elucidated in a
neonatal HI rat model. In this study, for the first time, we showed that overexpressing BI1, using an Ad-TMBIM6, administered intracerebroventricularly into the neonatal brain,
conferred protection after HI. Ad-TMBIM6 significantly reduced percent infarcted area,
attenuated neuronal apoptosis and long-term motor, learning and memory deficits.
Morphological analysis revealed lower percentage of tissue loss in animals
overexpressing BI-1 versus animals in vehicle group. These protective effects were
observed to be via inhibition of the IRE1α branch of the ER stress response signaling
pathway.
In conjunction with activating the UPR and initiating pro-apoptotic signaling, ER
stress has also been linked with increased reactive oxygen species (ROS) which leads to
oxidative stress and inflammation (Cao et al. , 2014; Zeeshan et al. , 2016). HI can
trigger a robust inflammatory response prompting the activation of inflammatory cells in
the brain which exacerbates brain injury (Zhao et al. , 2016). ROS is generated due to
activation of these inflammatory cells, which further contributes to the activation of proinflammatory mediators. Apart from BI-1’s role as an anti-apoptotic protein and its
ability to attenuate the UPR response, it has also been implicated in its ability to reduce
ROS (Kawai-Yamada et al. , 2004; Kim et al. , 2009; Henke et al. , 2011).
Overexpression of BI-1 reduced ROS and attenuated oxidative damage (Kim et
al. , 2009). A major contributor to ROS generation during ER stress is from the
microsomal monooxygenase system (MMO). This occurs as a result of electron leakage
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between NPR and the major component of the MMO system, P4502E1 (CYP).
Specifically, P4502E1 activity was increased in response to ER stress inducers,
thapsigargin, while BI-1 overexpressing cells inhibited P4502E1 expression (Kim et al. ,
2009). Levels of P4502E1 were lower in BI-1 cells versus wildtype, which was consistent
with lower levels of ROS accumulation. Although BI-1 attenuates P4502E1 expression
and activity, a clear interaction between these two has not been shown. Instead, coimmunoprecipitation studies have shown a physical interaction to exist between BI-1 and
NPR (Kim et al. , 2009). It has been suggested that BI-1 may induce dissociation of the
NPR-CYP complex by directly binding to NPR and reducing the electron transfer
between these two and hence reducing ROS (Kim et al. , 2009). A second possible
mechanism of BI-1 protection against ROS is via upregulation of anti-oxidant factors,
such as Nrf-2 and HO-1. Cells overexpressing BI-1 have higher levels of Nrf-2 and HO1, which was linked to a reduction in ROS (Lee et al. , 2007).
To examine this possibility after neonatal HI injury, we tested this pathway in a
rat subjected to unilateral carotid artery ligation, followed by hypoxia to induce HI injury.
We used siRNAs to silence BI-1 or Nrf-2 and detected that silencing of BI-1 increased
P4502E1 expression levels, which was correlated with an increase in ROS and
inflammatory mediators. In addition, silencing of Nrf-2 showed similar results.
Furthermore, rats that were administered Ad-TMBIM6 without siRNAs had significantly
reduced P4502E1 expression levels together with upregulation of Nrf-2 and HO-1 with
subsequent attenuation of ROS and inflammation. Here we showed that BI-1 can also
attenuate oxidative stress and inflammation via increased production of anti-oxidant
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enzymes coupled with destabilization of the NPR-CYP complex in a neonatal HI rat
model.
Understanding BI-1’s signaling mechanisms pertaining to inhibition of ER stress
induced injury after HIE is crucial in establishing how the two components interrelate.

Clinical Significance
Given the limited therapeutic options for hypoxic ischemic encephalopathy (HIE)
it is necessary to understand cellular and molecular mechanisms which can lead to more
effective therapeutic strategies. Hypothermia is the only therapy that has shown success
(Meloni 2008), but despite that, a large percentage of neonates still develop long-term
complications.
The lack of adequate mechanistic animal studies, therapeutic window, timing of
treatment and various other factors halt the progression of promising targets to be
translated to clinics.

Can BI-1 Be a Potential Therapeutic Target?
One must consider the plethora of signaling mechanisms that can be
activated/inhibited by BI-1. It can regulate calcium release, bind to and activate Bcl-2 and
inhibit Bax, attenuate UPR proteins activated as a result of ER stress, reduce production
of ROS and increase actin polymerization (Kim et al. , 2008; Henke et al. , 2011). BI-1’s
multimodal properties suggest that it can target a wide array of pathophysiological
consequences after HIE. Therefore, this makes BI-1 a potential therapeutic target and

143

may change the clinical management for patients with HI injury and provide a foundation
for future research in other types of strokes with similar pathologies
The only caveat is that there is a lack of in vivo studies showing BI-1’s diverse
roles. A vast majority of the studies have been done in cell culture models. Therefore, it
is imperative to translate those in vitro studies to in vivo disease models. Additionally,
BI-1’s anti-apoptotic roles might be detrimental in some disease processes such as in an
infection. For example, BI-1 may act in conjunction with pathogens to promote cell
survival of infected cells (Robinson et al. , 2011). Some pathogens contain molecules that
can bind with BI-1 and inhibit apoptosis, therefore, promoting survival of the infected
cell. One such molecule was found to be NIeH, that bound to BI-1 and decrease calcium
release during infection, thus blocking apoptosis (Hemrajani et al. , 2010). It is crucial to
determine all of BI-1’s functions and signaling mechanisms in a wide array of disease
models before it can be translated to clinical studies.

Conclusion
There has been considerable progress made in understanding BI-1 and its role in
apoptosis and disease. Despite that, the way in which it functions in stroke and other
disease models remains to be elucidated. We showed that overexpressing BI-1 in a
neonatal rat brain conferred protection after HI injury by reducing apoptosis and
oxidative stress. Agonizing the effects of ER stress with silencing either BI-1 or the antioxidant transcription factor Nrf-2, or further upregulating IRE1α signaling, exacerbated
the injury even with Ad-TMBIM6 vector administration.
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With this study we identified a novel role for BI-1 protein and endoplasmic
reticulum stress in the pathophysiology of neonatal HI injury. We found that BI-1
conferred an inhibitory effect on IRE1α signaling thus attenuating apoptosis.
Additionally, we showed that BI-1 inhibited P4502E1, major component for ROS
production, coupled with upregulation of anti-oxidant factors, Nrf-2 and HO-1, to
attenuate oxidative stress and inflammation after HI. Nonetheless, future studies are
needed to better understand BI-1’s role in ER stress which may aid in better
understanding how cells can overcome stresses. In summary there are still many aspects
to be answered about BI-1 and how it can regulate life and death.

Future Directions
In our study we focused on two general concepts: The effects of overexpressing
BI-1 in the neonatal rat brain using gene delivery of adenoviral-TMBIM6 vector, and the
mechanisms by which it confers its protective effects. Due to limited knowledge on BI-1
and thereafter serious lack of specific drugs targeting it, we used an adenoviral vector to
over express the TMBIM6 gene, which can overexpress BI-1 protein. However, using
adenoviral vectors takes multiple days to begin expressing, causing a delay in treatment
and possibly missing the optimal therapeutic window. Further exploration and
development of more adequate ways to target BI-1 overexpression in vivo are needed.
Additionally, we injected the virus intracerebroventricularly, future research into more
clinically translatable routs is necessary.
Our study focused on BI-1’s role in ER stress after neonatal HIE, however, there
are many other areas yet to be investigated in various other stroke models and diseases.
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The protection conferred after HIE in this study via inhibition of IRE1α and dissociation
of the NPR-CYP complex may not be optimal in other models of disease. Further research
is necessary to see BI-1’s role in diseases and potential alternative pathways that may be
involved. There is a possibility that BI-1’s effects extend beyond the ER stress mechanisms
and these need to be evaluated in subsequent studies.
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